<!DOCTYPE html>
<!-- saved from url=(0083)https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm -->
<html class="" data-reactroot=""><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><script src="./120.己烯雌酚 - 搜狗科学百科_files/analytics.js.download" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app226.us.archive.org';v.server_ms=260;archive_analytics.send_pageview({});});</script>
<script type="text/javascript" src="./120.己烯雌酚 - 搜狗科学百科_files/bundle-playback.js.download" charset="utf-8"></script>
<script type="text/javascript" src="./120.己烯雌酚 - 搜狗科学百科_files/wombat.js.download" charset="utf-8"></script>
<script type="text/javascript">
  __wm.init("https://web.archive.org/web");
  __wm.wombat("https://baike.sogou.com/kexue/d10120.htm","20221029032313","https://web.archive.org/","web","/_static/",
	      "1667013793");
</script>
<link rel="stylesheet" type="text/css" href="./120.己烯雌酚 - 搜狗科学百科_files/banner-styles.css">
<link rel="stylesheet" type="text/css" href="./120.己烯雌酚 - 搜狗科学百科_files/iconochive.css">
<!-- End Wayback Rewrite JS Include -->
<meta name="save" content="history"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="baidu-site-verification" content="VWGb6TyYx8"><meta content="己烯雌酚 - 搜狗科学百科" name="keywords"><meta content="搜狗科学百科是一部有着平等、协作、分享、自由理念的网络科学全书，为每一个互联网用户创造一个涵盖所有领域知识、服务的中文知识性平台。" name="description"><meta http-equiv="x-dns-prefetch-control" content="on"><meta name="server" baike="235" ip="210" env="online"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://cache.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://hhy.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://pic.baike.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://ugc.qpic.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://xui.ptlogin2.qq.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://q1.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://q2.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://q3.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://q4.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://q.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://img01.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://img02.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://img03.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221029032313/https://img04.sogoucdn.com/"><link rel="Shortcut Icon" href="https://web.archive.org/web/20221029032313im_/https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link rel="Bookmark" href="https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link href="./120.己烯雌酚 - 搜狗科学百科_files/base_b849887.css" rel="stylesheet"><link href="./120.己烯雌酚 - 搜狗科学百科_files/detail_378aed5.css" rel="stylesheet"><link href="./120.己烯雌酚 - 搜狗科学百科_files/inviteAudit_7894507.css" rel="stylesheet"><link rel="stylesheet" href="./120.己烯雌酚 - 搜狗科学百科_files/highlight.min.css"><title>己烯雌酚 - 搜狗科学百科</title><style>.onekey-close {
	position: absolute;
	top: 16px;
	right: 16px;
	width: 24px;
	height: 24px;
	background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	text-indent: -999em;
	background-size: 84px;
	background-position: -63px 0;
}

.onekey-login {
	position: absolute;
	top: 16.4%;
	left: 0;
	right: 0;
	width: 100%;
}

/* .onekey-login-img {
    width: 75px;
    height: 75px;
    background: url("https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/images/sprite_wap_baike.png") no-repeat;
    background-size: 100px 91px;
    background-position: 0 0;
    background-repeat: no-repeat;
    margin: 0 auto;
} */

.onekey-login-title {
	text-align: center;
	padding-bottom: 3px;
	font-size: 21px;
	font-weight: bold;
	line-height: 30px;
	color: #000;
}

.onekey-login-txt {
	text-align: center;
	font-family: PingFangSC;
	font-size: 14px;
	line-height: 20px;
	color: #8f8f8f;
}

.onekey-login-qq,
.onekey-login-wx,
.onekey-login-phone {
	display: block;
	width: 245px;
	height: 54px;
	border-radius: 45px;
	text-align: center;

	margin: 0 auto;
	font-size: 17px;
	line-height: 24px;
	color: #000;
	/* padding: 16px 77px; */
	border-radius: 12px;
	border: solid 1px #e0e0e0;
}
.onekey-qq-content,
.onekey-vx-content,
.onekey-phone-content {
	display: inline-block;
	margin-top: 16px;
}
.onekey-qq-content {
	padding: 0 5px;
}

.onekey-login-qq {
	margin-top: 48px;
	margin-bottom: 24px;
}

.onekey-login-qq:before {
	display: inline-block;
	content: "";
	width: 20px;
	height: 20px;
	background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 80px;
	background-position: -20px 0;
	vertical-align: top;
	margin: 17px 8px 0 0;
}

.onekey-login-wx {
	margin-bottom: 24px;
}

.onekey-login-wx:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: 0 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-login-phone {
}

.onekey-login-phone:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: -42px 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-fixed {
	z-index: 100;
	position: fixed;
	top: 0;
	bottom: 0;
	left: 0;
	right: 0;
	background: #fff;
	width: 100%;
	height: 100%;
}

.onekey-fixed.forbid {
	z-index: 100;
	position: fixed;
	top: auto;
	bottom: 68px;
	left: 9%;
	right: 0;
	background: rgba(0, 0, 0, 0.7);
	width: 82%;
	height: 43px;
	border-radius: 25px;
	color: #ffffff;
}
.onekey-login-title.forbid {
	text-align: center;
	padding-bottom: 3px;
	font-size: 14px;
	font-weight: normal;
	line-height: 30px;
	color: white;
}
</style><style>#login_mask {
  background: #000;
  opacity: 0.5;
  filter: alpha(opacity=50);
  position: fixed;
  /*fixed好像在哪个IE上有BUG，先用用*/
  left: 0;
  top: 0;
  z-index: 999;
  height: 100%;
}

#login_iframe_container {
  position: fixed;
  width: 550px;
  height: 360px;
  z-index: 1020;
  background-color: #ffffff;
}

@media screen and (max-width: 828px) {
  #login_iframe_container {
    top: 50% !important;
    left: 50% !important;
    transform: translate(-50%, -50%);
  }
}

#login_iframe_container.new-login {
  width: 550px;
  height: 360px;
  background-image: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/background_2a4a8a6.png);
}

#login_iframe_container.new-login.no-bg {
  background: #fff;
}

#login_iframe_container.new-login .login-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 30px;
  letter-spacing: 0.19px;
  color: #ffffff;
  margin-top: 62px;
}
#login_iframe_container.new-login .forbid-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 24px;
  letter-spacing: 0.19px;
  color: #333333;
  margin-top: 150px;
}

#login_iframe_container.new-login.no-bg .login-title {
  color: #333333;
}

#login_iframe_container.new-login .login-subtitle {
  width: 100%;
  height: 18px;
  line-height: 18px;
  font-size: 13px;
  letter-spacing: 0.08px;
  color: #ffffff;
  text-align: center;
  margin-top: 9px;
  margin-bottom: 43px;
}

#login_iframe_container.new-login.no-bg .login-subtitle {
  color: #999999;
}

#login_iframe_container.new-login .login-subtitle::before {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: -5px;
}

#login_iframe_container.new-login .login-subtitle::after {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: 5px;
}

#login_iframe_container.new-login.no-bg .login-subtitle::before {
  background-color: #999999;
}

#login_iframe_container.new-login.no-bg .login-subtitle::after {
  background-color: #999999;
}

#login_iframe_container.new-login .close-btn {
  position: absolute;
  top: 20px;
  right: 20px;
  width: 12px;
  height: 12px;
  background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -59px -10px;
  background-size: 81px 91px;
  cursor: pointer;
}

#login_iframe_container.new-login .login-btn {
  width: 220px;
  height: 47px;
  border-radius: 24px;
  border: solid 1px #dddddd;
  background-color: #ffffff;
  margin: 0 auto;
  margin-top: 28px;
  position: relative;
  display: block;
}

#login_iframe_container.new-login .login-btn .login-icon {
  position: absolute;
}

#login_iframe_container.new-login .login-btn .login-text {
  width: 61px;
  height: 47px;
  line-height: 47px;
  vertical-align: middle;
  font-size: 15px;
  letter-spacing: 0.1px;
  color: #666666;
  position: absolute;
  right: 62px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-icon {
  width: 22px;
  height: 27px;
  top: 10px;
  left: 67px;
  background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -54px;
  background-size: 81px 91px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-text {
  right: 59px;
}

#login_iframe_container.new-login .login-btn.wechat-btn .login-icon {
  width: 29px;
  height: 24px;
  top: 12px;
  left: 62px;
  background: url(//web.archive.org/web/20221029045211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -10px;
  background-size: 81px 91px;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style>
<!--百度统计-->
<script>
   var _hmt = _hmt || [];
   (function() {
      var hm = document.createElement("script");
      hm.src = "https://hm.baidu.com/hm.js?3c7614be3026469d5a60f41ab30b5082";
      var s = document.getElementsByTagName("script")[0]; 
      s.parentNode.insertBefore(hm, s);
      })();
</script>

	<!--百度统计-->
	<script>
		var _hmt = _hmt || [];
		(function() {
			var hm = document.createElement("script");
			hm.src = "https://hm.baidu.com/hm.js?3c7614be3026469d5a60f41ab30b5082";
			var s = document.getElementsByTagName("script")[0]; 
			s.parentNode.insertBefore(hm, s);
			})();
	</script>
</head>
<body class=""><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
</style>
<script>__wm.rw(0);</script>
<div id="wm-ipp-base" lang="en" style="display: block; direction: ltr;">
</div><div id="wm-ipp-print">The Wayback Machine - https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm</div>
<script type="text/javascript">//<![CDATA[
__wm.bt(675,27,25,2,"web","https://baike.sogou.com/kexue/d10120.htm","20221029032313",1996,"/_static/",["/_static/css/banner-styles.css?v=S1zqJCYt","/_static/css/iconochive.css?v=qtvMKcIJ"], false);
  __wm.rw(1);
//]]></script>
<!-- END WAYBACK TOOLBAR INSERT --><script>window._gtag=window._gtag||{};window._gtag.shouldGrayed = false;if ('9cee957f26b743c586fb37190bbe88a6') window._gtag.traceId = '9cee957f26b743c586fb37190bbe88a6';if ({"illegality":true}) window.userInfo = {"illegality":true};</script><div class="topnavbox"><ul class="topnav"><li><a href="https://web.archive.org/web/20221029032313/https://www.sogou.com/web?query=">网页</a></li><li><a href="https://web.archive.org/web/20221029032313/https://weixin.sogou.com/weixin?p=75351201">微信</a></li><li><a href="https://web.archive.org/web/20221029032313/https://zhihu.sogou.com/zhihu?p=75351218">知乎</a></li><li><a href="https://web.archive.org/web/20221029032313/https://pic.sogou.com/pics?query=">图片</a></li><li><a href="https://web.archive.org/web/20221029032313/https://v.sogou.com/v?query=">视频</a></li><li><a href="https://web.archive.org/web/20221029032313/https://mingyi.sogou.com/">医疗</a></li><li class="cur"><strong>科学</strong></li><li><a href="https://web.archive.org/web/20221029032313/https://hanyu.sogou.com/">汉语</a></li><li><a href="https://web.archive.org/web/20221029032313/https://wenwen.sogou.com/">问问</a></li><li><a href="https://web.archive.org/web/20221029032313/https://www.sogou.com/docs/more.htm">更多<span class="topraquo">»</span></a></li></ul></div><div id="header"><div class="header-wrap"><a class="header-logo" href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue"></a><div class="header-search"><div class="querybox" id="suggBox"><form><input id="searchInput" class="query" type="text" placeholder="搜科学领域专业百科词条" name="query" autocomplete="off" value=""><a href="javascript:;" class="query-search"></a></form></div></div><div class="header-rgt"><span class="btn-header-rgt btn-edit" id="editLemma">创建</span><div class="header-user no-login"></div></div></div></div><div class="fixed-placeholder" style="visibility:none"></div><div id="container" class=""><div class="content lemma-level1"><div class="detail-title" id="abstract-title"><h1>己烯雌酚</h1><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#!" class="detail-edit">编辑</a></div><div class="section_content" data-id="51190979050383111"><div class="text_img ed_imgfloat_right"><a class="ed_image_link" data-src="https://img03.sogoucdn.com/app/a/200698/1080_474_20200819113542-273547600.jpg" data-bigsrc="https://img03.sogoucdn.com/app/a/200698/1080_474_20200819113542-273547600.jpg?width=231&amp;height=174&amp;titlename=%E5%B7%B1%E7%83%AF%E9%9B%8C%E9%85%9A%E5%88%86%E5%AD%90%E5%BC%8F&amp;w=1080&amp;h=474" title="点击查看大图" data-w="1080" data-h="474" style="background-image:url(https://web.archive.org/web/20221029032313im_/https://img03.sogoucdn.com/app/a/200698/1080_474_20200819113542-273547600.jpg)" href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#!"></a><div class="text_img_title" style="text-align: center;">己烯雌酚分子式</div></div><div><p>己烯雌酚（DES），也称为苯乙烯雌酚，是一种雌激素药物，但现已几乎不再使用。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_1" class="kx_ref">[1]</a></sup> 过去，它被广泛用于各种适应症，包括对有反复流产史的妇女的妊娠支持、对妇女更年期症状和雌激素缺乏的激素治疗、对男性前列腺癌和女性乳腺癌的治疗以及其他用途。虽然口服给药最常见，但也可通过其他途径使用，如阴道给药、局部给药和注射给药。</p>
<p>DES是雌激素或雌激素受体的激动剂，是雌二醇等雌激素的生物学靶点。 它是芪类合成的非甾体雌激素，在各方面均不同于天然雌激素雌二醇。 与雌二醇相比，口服DES大大提高了生物利用度，更能抵抗新陈代谢，并在身体的某些部位（如肝脏和子宫）显示出相对增强的效果。 这些差异导致DES在血栓、心血管问题和某些其他副作用上的风险增加。</p>
<p>DES于1938年被发现。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_2" class="kx_ref">[2]</a></sup> 从1940年到1971年，这种药物被用来给孕妇服用，并被错误地认为会降低妊娠并发症和流产的风险。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_2" class="kx_ref">[2]</a></sup> 1971年，人们发现DES能够在子宫内接触过这种药物的女孩和妇女中引起透明细胞癌，这是一种罕见的阴道肿瘤。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_2" class="kx_ref">[2]</a></sup> 随后，美国食品和药物管理局撤销了对DES作为孕妇治疗方法的批准。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_2" class="kx_ref">[2]</a></sup> 后续研究表明，DES也有可能在接触者的生命周期内引起各种严重的不良医疗并发症。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_2" class="kx_ref">[2]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_3" class="kx_ref">[3]</a></sup> </p>
<p>美国国家癌症研究所建议<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_4" class="kx_ref">[4]</a></sup> 服用过DES的婴儿母亲定期接受特殊医学检查，以筛查药物治疗引起的并发症。母亲怀孕期间接触DES的人通常被称为“DES女儿”和“DES儿子”。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_2" class="kx_ref">[2]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_5" class="kx_ref">[5]</a></sup> 自从发现DES的毒性作用后，它基本上已经停止使用，现在基本上不再投入市场。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_2" class="kx_ref">[2]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_6" class="kx_ref">[6]</a></sup> </p></div></div><div id="catalog"><h2 class="title2">目录<a href="javascript:" class="detail-edit">编辑</a></h2><div class="catalog_wrap" style=""><ul class="catalog_list col3"><li><span class="order">1</span><a href="javascript:" data-level="1" data-id="14994946826174978">医疗用途</a></li><li><span class="order">2</span><a href="javascript:" data-level="1" data-id="14994946826174979">副作用</a></li><li class="secondary_catalog"><span>2.1 </span><a href="javascript:" data-id="14994946826174979">长期影响</a></li><li><span class="order">3</span><a href="javascript:" data-level="1" data-id="14994946842952194">用药过量</a></li><li><span class="order">4</span><a href="javascript:" data-level="1" data-id="14994946842952195">药理学</a></li><li class="secondary_catalog"><span>4.1 </span><a href="javascript:" data-id="14994946842952195">药效学</a></li></ul><ul class="catalog_list col3"><li class="secondary_catalog"><span>4.2 </span><a href="javascript:" data-id="14994946842952195">药代动力学</a></li><li><span class="order">5</span><a href="javascript:" data-level="1" data-id="14994946842952196">化学</a></li><li><span class="order">6</span><a href="javascript:" data-level="1" data-id="14994946859729414">历史</a></li><li class="secondary_catalog"><span>6.1 </span><a href="javascript:" data-id="14994946859729414">合成</a></li><li class="secondary_catalog"><span>6.2 </span><a href="javascript:" data-id="14994946859729414">临床应用</a></li><li class="secondary_catalog"><span>6.3 </span><a href="javascript:" data-id="14994946859729414">诉讼</a></li></ul><ul class="catalog_list col3"><li><span class="order">7</span><a href="javascript:" data-level="1" data-id="14994946859729415">社会和文化</a></li><li><span class="order">8</span><a href="javascript:" data-level="1" data-id="14994946859729416">兽医用途</a></li><li class="secondary_catalog"><span>8.1 </span><a href="javascript:" data-id="14994946859729416">犬失禁</a></li><li class="secondary_catalog"><span>8.2 </span><a href="javascript:" data-id="14994946859729416">牲畜生长促进</a></li><li><span class="order">9</span><a href="javascript:" data-level="1" data-id="references">参考文献</a></li></ul></div></div><div id="paragraphs"><div><div id="par_14994946826174978"><h2 class="title">1 医疗用途<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>DES在过去被用于以下适应症：<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_7" class="kx_ref">[7]</a></sup> </p><p>
 </p><ul>
  <li>怀孕期间反复流产</li>
  <li>更年期激素疗法，用于治疗更年期症状，如热潮红和阴道萎缩</li>
  <li>雌激素过少症的激素治疗（例如性腺发育不良、卵巢早衰和卵巢切除术后）</li>
  <li>抑制产后泌乳以防止或逆转乳房充血</li>
  <li>淋病性阴道炎（抗生素青霉素采用后停用）</li>
  <li>前列腺癌和乳腺癌</li>
  <li>青春期女孩身材高大的预防</li>
  <li>作为性交后的紧急避孕药</li>
  <li>作为化学阉割的一种手段，用于男性性欲亢进和性欲倒错以及性犯罪者促性腺激素释放激素</li>
  <li>在促性腺激素释放激素激动剂（GnRH激动剂）疗法开始时抑制睾丸激素升高<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_8" class="kx_ref">[8]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_9" class="kx_ref">[9]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_10" class="kx_ref">[10]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_11" class="kx_ref">[11]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_12" class="kx_ref">[12]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_13" class="kx_ref">[13]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_14" class="kx_ref">[14]</a></sup></li>
 </ul><p></p><p>人们对使用DES治疗男性前列腺癌的兴趣一直持续到今天。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_15" class="kx_ref">[15]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_16" class="kx_ref">[16]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_17" class="kx_ref">[17]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_18" class="kx_ref">[18]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_19" class="kx_ref">[19]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_20" class="kx_ref">[20]</a></sup> 然而，一些研究人员主张使用生物识别的胃肠外雌激素，如聚乙二醇磷酸酯，而不是口服合成雌激素，如DES，因为它们的心血管毒性风险低得多。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_21" class="kx_ref">[21]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_18" class="kx_ref">[18]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_20" class="kx_ref">[20]</a></sup> 除了前列腺癌之外，人们对使用DES治疗女性乳腺癌的兴趣也持续到今天。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_22" class="kx_ref">[22]</a></sup> 然而，与前列腺癌的情况相似，一些研究人员主张使用生物识别雌激素，如雌二醇，而不是DES，来治疗乳腺癌。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_23" class="kx_ref">[23]</a></sup> </p><p>
 </p><table class="wikitable">
  <tbody>
   <tr>
    <td colspan="3">雌激素用于乳腺癌的剂量</td>
   </tr>
   <tr>
    <td>路径/形式</td>
    <td>雌激素</td>
    <td>剂量</td>
   </tr>
   <tr>
    <td rowspan="6">口服</td>
    <td>雌二醇</td>
    <td>10毫克3次/天<p>抗AI：2毫克1-3次/天</p></td>
   </tr>
   <tr>
    <td>雌二醇戊酸酯</td>
    <td>抗AI：2毫克1-3次/天</td>
   </tr>
   <tr>
    <td>共轭雌激素</td>
    <td>10毫克3次/天</td>
   </tr>
   <tr>
    <td>炔雌醇</td>
    <td>0.5–1毫克3次/天</td>
   </tr>
   <tr>
    <td>己烯雌酚</td>
    <td>5毫克3次/天</td>
   </tr>
   <tr>
    <td>双烯雌酚</td>
    <td>5毫克3次/天</td>
   </tr>
   <tr>
    <td rowspan="5">肠内注射或皮下注射</td>
    <td>苯甲酸雌二醇</td>
    <td>每周5毫克2-3次</td>
   </tr>
   <tr>
    <td>二丙酸雌二醇</td>
    <td>每周5毫克3次</td>
   </tr>
   <tr>
    <td>雌二醇戊酸酯</td>
    <td>30毫克1次/2周</td>
   </tr>
   <tr>
    <td>聚雌二醇磷酸酯</td>
    <td>40–80毫克1次/4周</td>
   </tr>
   <tr>
    <td>雌酮</td>
    <td>5毫克≥3次/周</td>
   </tr>
   <tr>
    <td colspan="3">注：（1）仅适用于绝经至少5年的女性。（2）剂量不一定相等。</td>
   </tr>
   <tr>
    <td colspan="3">雌激素用于前列腺癌的剂量</td>
   </tr>
   <tr>
    <td>路径/形式</td>
    <td>雌激素</td>
    <td>剂量</td>
   </tr>
   <tr>
    <td rowspan="11">口服</td>
    <td>雌二醇</td>
    <td>1-2毫克3次/天</td>
   </tr>
   <tr>
    <td>共轭雌激素</td>
    <td>1.25–2.5毫克3次/天</td>
   </tr>
   <tr>
    <td>炔雌醇</td>
    <td>0.15–2毫克/天</td>
   </tr>
   <tr>
    <td>炔雌醇磺酸盐</td>
    <td>每周1-2毫克1次</td>
   </tr>
   <tr>
    <td>己烯雌酚</td>
    <td>1-3毫克/天</td>
   </tr>
   <tr>
    <td>双烯雌酚</td>
    <td>5毫克/天</td>
   </tr>
   <tr>
    <td>己烷雌酚</td>
    <td>5毫克/天</td>
   </tr>
   <tr>
    <td>磷雌酚</td>
    <td>每天120-480毫克1-3次</td>
   </tr>
   <tr>
    <td>氯烯雌醚</td>
    <td>12-24毫克/天</td>
   </tr>
   <tr>
    <td>夸屈硅烷</td>
    <td>900毫克/天</td>
   </tr>
   <tr>
    <td>雌莫司汀磷酸盐</td>
    <td>140-1400毫克/天</td>
   </tr>
   <tr>
    <td>透皮贴剂</td>
    <td>雌二醇</td>
    <td>2–6x 100μg/天<p>阴囊：1x 100微克/天</p></td>
   </tr>
   <tr>
    <td rowspan="6">肠内注射或皮下注射</td>
    <td>苯甲酸雌二醇酯</td>
    <td>每周1.66毫克3次</td>
   </tr>
   <tr>
    <td>二丙酸雌二醇酯</td>
    <td>每周5毫克1次</td>
   </tr>
   <tr>
    <td>雌二醇戊酸酯</td>
    <td>10-40毫克1次/1-2周</td>
   </tr>
   <tr>
    <td>十一酸雌二醇酯</td>
    <td>100毫克1次/4周</td>
   </tr>
   <tr>
    <td>聚乙二醇磷酸酯</td>
    <td>单独使用：160–320毫克1次/4周<p>口服EE：40–80毫克1次/4周</p></td>
   </tr>
   <tr>
    <td>雌酮</td>
    <td>每周2-4毫克2-3次</td>
   </tr>
   <tr>
    <td rowspan="2">静脉注射</td>
    <td>磷雌酚</td>
    <td>每周300-1200毫克1-7次</td>
   </tr>
   <tr>
    <td>雌莫司汀磷酸盐</td>
    <td>240–450毫克/天</td>
   </tr>
   <tr>
    <td colspan="3">注意：剂量不一定相等。</td>
   </tr>
  </tbody>
 </table><p></p></div></div><div id="par_14994946826174979"><h2 class="title">2 副作用<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>口服剂量超过1毫克/天时，DES的副作用发生率较高，包括恶心、呕吐、腹部不适、头痛和腹胀，发生率为15%至50%。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_24" class="kx_ref">[24]</a></sup> </p><p>在以DES作为一种男性前列腺癌高剂量雌激素疗法形式的研究中，DES与心血管发病率和死亡率有很大关系。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_25" class="kx_ref">[25]</a></sup> 风险取决于剂量。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_25" class="kx_ref">[25]</a></sup> 5毫克/天的DES剂量与36%的非癌症（主要是心血管）死亡增长相关。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_25" class="kx_ref">[25]</a></sup> 此外，静脉血栓栓塞的发生率高达15%。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_25" class="kx_ref">[25]</a></sup> 3毫克/天的DES剂量与9.6%至17%的血栓栓塞发生率相关，心血管并发症发生率为33.3%。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_25" class="kx_ref">[25]</a></sup> 1毫克/天的低剂量DES与14.8%的心血管事件导致的死亡率相关（与之相比，单纯睾丸切除术的死亡率为8.3%）。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_25" class="kx_ref">[25]</a></sup> </p><p>在接受前列腺癌治疗的男性中，发现DES会产生41%至77%的男性乳房发育症（乳房发育）。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_26" class="kx_ref">[26]</a></sup> </p><p></p><h3>2.1 <span>长期影响</span></h3><p></p><p>DES与多种长期不良反应有关，如在怀孕期间接受DES治疗的妇女和/或其后代患阴道透明细胞腺癌、阴道腺病、T形子宫、子宫肌瘤、宫颈机能不全、乳腺癌、不孕症、性腺机能减退、间体缺陷、抑郁症等的风险增加。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_27" class="kx_ref">[27]</a></sup> </p></div></div><div id="par_14994946842952194"><h2 class="title">3 用药过量<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>在过去的临床研究中，高达1500毫克/天的DES被评估为极高剂量。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_28" class="kx_ref">[28]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_28" class="kx_ref">[28]</a></sup> </p></div></div><div id="par_14994946842952195"><h2 class="title">4 药理学<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><h3>4.1 <span>药效学</span></h3><p></p><p><strong>雌激素活性</strong></p><p>DES是一种雌激素；具体而言，它是两种雌激素受体（ERs）的高效全激动剂。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_29" class="kx_ref">[29]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_30" class="kx_ref">[30]</a></sup> DES对雌激素受体α和雌激素受体β的亲和力分别约为468%和295%。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_31" class="kx_ref">[31]</a></sup> 然而，据报道，DES与雌激素受体α和雌激素受体β的EC50值分别为0.18 nM和0.06 nM，这表明，尽管DES与两种受体具有结合亲和力，但对于雌激素受体β的激活比雌激素受体α高出数倍。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_32" class="kx_ref">[32]</a></sup> </p><p>就全身雌激素效力而言，1毫克/天DES的剂量大约相当于50克/天炔雌醇的剂量。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_33" class="kx_ref">[33]</a></sup> 与炔雌醇相似，DES对肝脏蛋白质合成有显著且不成比例的强烈作用。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_34" class="kx_ref">[34]</a></sup> 尽管其系统雌激素效力约是与微粉化雌二醇具有相似效力的雌酮酯（硫酸哌嗪雌酮）的3.8倍，但DES的肝脏雌激素效力是雌酮酯的28.4倍（或具有同等系统雌激素效力的剂量的约7.5倍强效力）。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_33" class="kx_ref">[33]</a></sup> </p><p>DES在治疗男性前列腺癌中至少有三种作用机制。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_34" class="kx_ref">[34]</a></sup> 由于其抗促性腺激素的作用，它能够抑制性腺雄激素的产生，从而抑制循环雄激素水平；它可以刺激肝脏性激素结合球蛋白（SHBG）的产生，从而增加SHBG循环水平，降低循环中睾酮和二氢睾酮的游离分数；并且它可能对睾丸和前列腺具有直接的细胞毒性作用。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_34" class="kx_ref">[34]</a></sup> 此外，高剂量的DES会减少脱氧核糖核酸的合成。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_34" class="kx_ref">[34]</a></sup> </p><p>DES是一种长效雌激素，细胞核驻留时间约为24小时。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_35" class="kx_ref">[35]</a></sup> </p><p>
 </p><div class="shadow-tb show-rgt"><table class="wikitable">
  <tbody>
   <tr>
    <td colspan="18">雌激素的相对口服功效</td>
   </tr>
   <tr>
    <td>雌激素</td>
    <td colspan="2">类型</td>
    <td colspan="2">HF</td>
    <td>VE</td>
    <td>UCa</td>
    <td colspan="2">FSH</td>
    <td colspan="2">LH</td>
    <td>HDL-C</td>
    <td>SHBG</td>
    <td colspan="2">CBG</td>
    <td colspan="2">AGT</td>
    <td>Liver</td>
   </tr>
   <tr>
    <td>雌二醇</td>
    <td colspan="2">生物识别</td>
    <td colspan="2">1</td>
    <td>1</td>
    <td>1</td>
    <td colspan="2">1</td>
    <td colspan="2">1</td>
    <td>1</td>
    <td>1</td>
    <td colspan="2">1</td>
    <td colspan="2">1</td>
    <td>1</td>
   </tr>
   <tr>
    <td>雌酮</td>
    <td colspan="2">生物识别</td>
    <td colspan="2">？</td>
    <td>？</td>
    <td>？</td>
    <td colspan="2">0.3</td>
    <td colspan="2">0.3</td>
    <td>？</td>
    <td>？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td>？</td>
   </tr>
   <tr>
    <td>雌三醇</td>
    <td colspan="2">生物识别</td>
    <td colspan="2">0.3</td>
    <td>0.3</td>
    <td>0.1</td>
    <td colspan="2">0.3</td>
    <td colspan="2">0.3</td>
    <td>0.2</td>
    <td>？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td>0.67</td>
   </tr>
   <tr>
    <td>雌酮硫酸盐</td>
    <td colspan="2">生物识别</td>
    <td colspan="2">？</td>
    <td>0.9</td>
    <td>0.9</td>
    <td colspan="2">0.9</td>
    <td colspan="2">0.9</td>
    <td>0.5</td>
    <td>0.9</td>
    <td colspan="2">0.7</td>
    <td colspan="2">1.5</td>
    <td>0.56–1.7</td>
   </tr>
   <tr>
    <td>共轭雌激素</td>
    <td colspan="2">天然的</td>
    <td colspan="2">1.2</td>
    <td>1.5</td>
    <td>2</td>
    <td colspan="2">1.1</td>
    <td colspan="2">1</td>
    <td>1.5</td>
    <td>3</td>
    <td colspan="2">1.5</td>
    <td colspan="2">5</td>
    <td>1.3–4.5</td>
   </tr>
   <tr>
    <td>硫酸木贼素</td>
    <td colspan="2">天然的</td>
    <td colspan="2">？</td>
    <td>？</td>
    <td>1</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td>6</td>
    <td>7.5</td>
    <td colspan="2">6</td>
    <td colspan="2">7.5</td>
    <td>？</td>
   </tr>
   <tr>
    <td>炔雌醇</td>
    <td colspan="2">合成的</td>
    <td colspan="2">120</td>
    <td>150</td>
    <td>400</td>
    <td colspan="2">120</td>
    <td colspan="2">100</td>
    <td>400</td>
    <td>500</td>
    <td colspan="2">600</td>
    <td colspan="2">350</td>
    <td>2.9–5.0</td>
   </tr>
   <tr>
    <td>己烯雌酚</td>
    <td colspan="2">合成的</td>
    <td colspan="2">？</td>
    <td>？</td>
    <td>？</td>
    <td colspan="2">3.4</td>
    <td colspan="2">？</td>
    <td>？</td>
    <td>25.6</td>
    <td colspan="2">24.5</td>
    <td colspan="2">19.5</td>
    <td>5.7–7.5</td>
   </tr>
   <tr>
    <td colspan="18">注：数值为比值，雌二醇为标准值（即1.0）。缩写：HF =热潮红的临床缓解。VE =阴道上皮细胞增殖增加。UCa =尿钙的降低。VE=卵泡刺激素水平的抑制。LH=黄体生成素水平的抑制。HDL-C、SHBG、CBG和AGT =这些肝脏蛋白质的血清水平增加。Liver=肝脏雌激素效应与全身/全身雌激素效应的比率（特别是热潮红缓解和促性腺激素抑制）。类型：生物识别=与在人类身上发现的相同。天然的=天然存在，但与人类中发现的不同（例如，其他物种的雌激素）。合成的=人造的，不会在动物或环境中自然发生。</td>
   </tr>
   <tr>
    <td colspan="18">雌激素的口服功效</td>
   </tr>
   <tr>
    <td colspan="2" rowspan="2">雌激素</td>
    <td colspan="2" rowspan="2">类型</td>
    <td colspan="2" rowspan="2">分类</td>
    <td colspan="2">ETD</td>
    <td colspan="2">EPD</td>
    <td colspan="2">EPD</td>
    <td colspan="2">MSD</td>
    <td colspan="2">MSD</td>
    <td colspan="2">TSD</td>
   </tr>
   <tr>
    <td colspan="2">（毫克/14天）</td>
    <td colspan="2">（毫克/14天）</td>
    <td colspan="2">（毫克/天）</td>
    <td colspan="2">（毫克/14天）</td>
    <td colspan="2">（毫克/天）</td>
    <td colspan="2">（毫克/天）</td>
   </tr>
   <tr>
    <td colspan="2">雌二醇（微粉化）</td>
    <td colspan="2">生物识别</td>
    <td colspan="2">类固醇</td>
    <td colspan="2">？</td>
    <td colspan="2">60–80</td>
    <td colspan="2">4.3</td>
    <td colspan="2">14–28岁</td>
    <td colspan="2">1.0–2.0</td>
    <td colspan="2">&gt; 8</td>
   </tr>
   <tr>
    <td colspan="2">雌二醇戊酸酯</td>
    <td colspan="2">生物识别</td>
    <td colspan="2">类固醇</td>
    <td colspan="2">6–10</td>
    <td colspan="2">60–80</td>
    <td colspan="2">4.3</td>
    <td colspan="2">14–28岁</td>
    <td colspan="2">1.0–2.0</td>
    <td colspan="2">&gt; 8</td>
   </tr>
   <tr>
    <td colspan="2">雌三醇</td>
    <td colspan="2">生物识别</td>
    <td colspan="2">类固醇</td>
    <td colspan="2">20<sup>a</sup> </td>
    <td colspan="2">120–150 ‑</td>
    <td colspan="2">10.0–10.7 <sup>b</sup> </td>
    <td colspan="2">28–84</td>
    <td colspan="2">1.0–6.0</td>
    <td colspan="2">？</td>
   </tr>
   <tr>
    <td colspan="2">雌三醇琥珀酸酯</td>
    <td colspan="2">生物识别</td>
    <td colspan="2">类固醇</td>
    <td colspan="2">？</td>
    <td colspan="2">140–150 <sup>b</sup> </td>
    <td colspan="2">10.0–10.7 <sup>b</sup> </td>
    <td colspan="2">28–84</td>
    <td colspan="2">2.0–6.0</td>
    <td colspan="2">？</td>
   </tr>
   <tr>
    <td colspan="2">共轭雌激素</td>
    <td colspan="2">天然的</td>
    <td colspan="2">类固醇</td>
    <td colspan="2">5–12</td>
    <td colspan="2">60–80</td>
    <td colspan="2">4.3</td>
    <td colspan="2">8.4–17.5</td>
    <td colspan="2">0.625–1.25</td>
    <td colspan="2">7.5</td>
   </tr>
   <tr>
    <td colspan="2">炔雌醇</td>
    <td colspan="2">合成的</td>
    <td colspan="2">类固醇</td>
    <td colspan="2">0.2</td>
    <td colspan="2">1.0–2.0</td>
    <td colspan="2">0.071–0.11</td>
    <td colspan="2">0.28</td>
    <td colspan="2">0.02</td>
    <td colspan="2">0.1</td>
   </tr>
   <tr>
    <td colspan="2">炔雌醇甲醚</td>
    <td colspan="2">合成的</td>
    <td colspan="2">类固醇</td>
    <td colspan="2">0.3</td>
    <td colspan="2">1.5–3.0</td>
    <td colspan="2">0.11–0.13</td>
    <td colspan="2">0.3–0.5</td>
    <td colspan="2">0.025</td>
    <td colspan="2">？</td>
   </tr>
   <tr>
    <td colspan="2">喹雌酮</td>
    <td colspan="2">合成的</td>
    <td colspan="2">类固醇</td>
    <td colspan="2">0.3</td>
    <td colspan="2">2.0–4.0</td>
    <td colspan="2">0.14–0.29</td>
    <td colspan="2">？</td>
    <td colspan="2">0.025–0.05</td>
    <td colspan="2">？</td>
   </tr>
   <tr>
    <td colspan="2">甲基雌二醇</td>
    <td colspan="2">合成的</td>
    <td colspan="2">类固醇</td>
    <td colspan="2">？</td>
    <td colspan="2">2</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
   </tr>
   <tr>
    <td colspan="2">己烯雌酚</td>
    <td colspan="2">合成的</td>
    <td colspan="2">非甾体化合物</td>
    <td colspan="2">2.5</td>
    <td colspan="2">20–30</td>
    <td colspan="2">1.4–2.1</td>
    <td colspan="2">？</td>
    <td colspan="2">0.5–2.0</td>
    <td colspan="2">3</td>
   </tr>
   <tr>
    <td colspan="2">二丙酸己烯雌酚</td>
    <td colspan="2">合成的</td>
    <td colspan="2">非甾体化合物</td>
    <td colspan="2">？</td>
    <td colspan="2">15–30</td>
    <td colspan="2">1.1–1.4</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
   </tr>
   <tr>
    <td colspan="2">双烯雌酚</td>
    <td colspan="2">合成的</td>
    <td colspan="2">非甾体化合物</td>
    <td colspan="2">？</td>
    <td colspan="2">30</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">0.5–4.0</td>
    <td colspan="2">？</td>
   </tr>
   <tr>
    <td colspan="2">双烯雌酚二乙酸酯</td>
    <td colspan="2">合成的</td>
    <td colspan="2">非甾体化合物</td>
    <td colspan="2">3–5</td>
    <td colspan="2">30–60</td>
    <td colspan="2">2.9–4.3</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
   </tr>
   <tr>
    <td colspan="2">己烷雌酚</td>
    <td colspan="2">合成的</td>
    <td colspan="2">非甾体化合物</td>
    <td colspan="2">？</td>
    <td colspan="2">70–110</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
   </tr>
   <tr>
    <td colspan="2">己烷雌酚二乙酸酯</td>
    <td colspan="2">合成的</td>
    <td colspan="2">非甾体化合物</td>
    <td colspan="2">？</td>
    <td colspan="2">45</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
   </tr>
   <tr>
    <td colspan="2">多口服</td>
    <td colspan="2">合成的</td>
    <td colspan="2">非甾体化合物</td>
    <td colspan="2">？</td>
    <td colspan="2">&gt; 100</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
   </tr>
   <tr>
    <td colspan="2">甲基雌激素</td>
    <td colspan="2">合成的</td>
    <td colspan="2">非甾体化合物</td>
    <td colspan="2">？</td>
    <td colspan="2">400</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
    <td colspan="2">？</td>
   </tr>
   <tr>
    <td colspan="18">注：EE的OID值为0.1毫克/天。脚注：a =变化很大，通常更高。b =分剂量，每天3次；不规则和不典型的扩散。</td>
   </tr>
   <tr>
    <td colspan="18">非甾体雌激素的胃肠外效力和持续时间</td>
   </tr>
   <tr>
    <td colspan="5">雌激素</td>
    <td colspan="4">ETD（14天）</td>
    <td colspan="9">期间</td>
   </tr>
   <tr>
    <td colspan="5">己烯雌酚</td>
    <td colspan="4">20毫克</td>
    <td colspan="4">3毫克≈ 3天</td>
    <td colspan="5"></td>
   </tr>
   <tr>
    <td colspan="5">二丙酸己烯雌酚</td>
    <td colspan="4">12.5-15毫克</td>
    <td colspan="4">2.5毫克≈ 5天</td>
    <td colspan="5"></td>
   </tr>
   <tr>
    <td colspan="5">己烯雌酚二丙酸酯（晶体。悬浊液。）</td>
    <td colspan="4">5毫克</td>
    <td colspan="4">？mg = 21-28天</td>
    <td colspan="5"></td>
   </tr>
   <tr>
    <td colspan="5">双烯雌酚二乙酸酯（晶体。susp。）</td>
    <td colspan="4">50毫克</td>
    <td colspan="4">？</td>
    <td colspan="5"></td>
   </tr>
   <tr>
    <td colspan="5">二甲己烯雌酚</td>
    <td colspan="4">20-40毫克</td>
    <td colspan="4">？</td>
    <td colspan="5"></td>
   </tr>
   <tr>
    <td colspan="5">二丙酸己雌醇酯</td>
    <td colspan="4">25毫克</td>
    <td colspan="4">？</td>
    <td colspan="5"></td>
   </tr>
   <tr>
    <td colspan="13">注：均为通过注射油剂，除非另有说明。</td>
    <td colspan="5"></td>
   </tr>
  </tbody>
 </table></div><p></p><p><strong>抗促性腺激素效应</strong></p><p>由于其雌激素活性，DES具有抗促性腺激素作用。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_36" class="kx_ref">[36]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_34" class="kx_ref">[34]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_37" class="kx_ref">[37]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_38" class="kx_ref">[38]</a></sup> 也就是说，它对下丘脑-垂体-性腺轴（HPG轴）施加负反馈，抑制促性腺激素、黄体生成素和卵泡刺激素的分泌，并抑制性激素的产生以及性腺中生殖细胞的产生或成熟。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_36" class="kx_ref">[36]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_34" class="kx_ref">[34]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_37" class="kx_ref">[37]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_38" class="kx_ref">[38]</a></sup> 在1至2周内以3毫克/天及以上的剂量下，DES持续地将男性睾酮水平抑制在阉割范围内（&lt; 50纳克/分升）。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_36" class="kx_ref">[36]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_38" class="kx_ref">[38]</a></sup> 相反，1毫克/天DES的剂量不能完全抑制男性睾酮水平进入阉割范围，而是通常使睾酮水平稳定在略高于阉割水平（&gt; 50纳克/分升）。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_39" class="kx_ref">[39]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_34" class="kx_ref">[34]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_37" class="kx_ref">[37]</a></sup> 然而，也有报道称，1毫克/天的DES可抑制约50%的睾酮水平，尽管个体间差异很大。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_36" class="kx_ref">[36]</a></sup> 据说每日剂量少于1毫克的DES对睾酮水平没有影响。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_36" class="kx_ref">[36]</a></sup> 然而，已发现向醋酸环丙孕酮中添加0.1毫克/天的“极低”剂量DES可产生协同抗促性腺激素的作用，并抑制男性睾酮水平进入阉割范围。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_39" class="kx_ref">[39]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_40" class="kx_ref">[40]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_41" class="kx_ref">[41]</a></sup> </p><p><strong>其他作用</strong></p><p>除了雌激素受体之外，一项体外研究发现，DES还对多种其他类固醇激素受体具有活性，虽然这些活性相对较弱。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_32" class="kx_ref">[32]</a></sup> 尽管研究发现雌激素受体α和雌激素受体β的半数致死浓度分别为0.18纳摩和0.06纳摩，但该药物在1微摩浓度下显示出明显的糖皮质激素活性，超过了0.1纳摩地塞米松的浓度，并且雄激素、孕酮和盐皮质激素受体具有明显的拮抗作用（分别为75%、85%和50%抑制阳性对照刺激，浓度均在1微摩）。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_32" class="kx_ref">[32]</a></sup>研究人员表示，据他们所知，他们是第一个报道DES这种作用的人，并假设这些作用可能与DES的临床效应有关，例如前列腺癌（特别是使用了特别高剂量的DES）。然而，他们也指出，这些作用的重要性需要在药理学相关剂量的动物模型中进一步研究。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_32" class="kx_ref">[32]</a></sup> </p><p>DES已被鉴定为三种同种类型雌激素相关受体（ERRs）：ERRα、ERRβ和ERRγ的拮抗剂。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_42" class="kx_ref">[42]</a></sup> </p><p></p><h3>4.2 <span>药代动力学</span></h3><p></p><p>口服DES吸收良好。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_33" class="kx_ref">[33]</a></sup> 口服剂量为1毫克/天时，最后一次剂量后20小时的血浆DES水平在0.9-1.9纳克/毫升（3.4-7.1纳摩尔/升）之间。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_33" class="kx_ref">[33]</a></sup> DES的分布半衰期为80分钟。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_33" class="kx_ref">[33]</a></sup> 它对SHBG或皮质类固醇结合球蛋白没有亲和力，因此在循环中不与这些蛋白质结合。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_43" class="kx_ref">[43]</a></sup> DES的血浆蛋白结合率大于95%。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_44" class="kx_ref">[44]</a></sup> DES芳环的羟基化和随后与乙基侧链的接合占DES代谢的80-90%，而氧化占剩余的10-20%，并且主要是结合反应。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_44" class="kx_ref">[44]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_45" class="kx_ref">[45]</a></sup> DES的结合包括葡萄糖醛酸化，而氧化包括脱氢成（Z，Z）-二烯雌酚。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_33" class="kx_ref">[33]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_44" class="kx_ref">[44]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_45" class="kx_ref">[45]</a></sup> 还已知该药物会产生作为代谢物的丙氧基丙酸。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_46" class="kx_ref">[46]</a></sup> DES产生短暂的醌类活性中间体，导致细胞和遗传损伤，这可能解释了DES对人类已知的致癌作用。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_33" class="kx_ref">[33]</a></sup> 然而，其他研究表明DES的毒性作用可能仅仅是由于ERs的过度激活。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_47" class="kx_ref">[47]</a></sup> DES的消除半衰期为24小时。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_33" class="kx_ref">[33]</a></sup> DES的代谢物通过尿液和粪便排出体外。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_44" class="kx_ref">[44]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_45" class="kx_ref">[45]</a></sup> </p></div></div><div id="par_14994946842952196"><h2 class="title">5 化学<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img03.sogoucdn.com/app/a/200698/sogou_science_1048" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title">雌二醇和DES的化学结构。[1] 注意DES中存在两个羟基，它们之间的距离与雌二醇两个羟基之间的距离相似，当认为DES是被偶然发现的时候，这一点值得注意。[1][2][3]</div>   
        </div> <p></p><p>DES属于二苯乙烯（4，4’-二羟基二苯乙烯）类化合物。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_48" class="kx_ref">[48]</a></sup> 它是甾体雌激素雌二醇的非甾体开环类似物。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_49" class="kx_ref">[49]</a></sup> DES源自天然化合物茴香脑，属于茴香和茴香籽的一种弱雌激素成分。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_48" class="kx_ref">[48]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_50" class="kx_ref">[50]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_51" class="kx_ref">[51]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_52" class="kx_ref">[52]</a></sup> 茴香脑脱甲基形成对丙烯基苯酚，然后对丙烯基苯酚自发二聚成二乙醇和己烷雌酚，DES随后通过己烷雌酚的结构修饰合成。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_48" class="kx_ref">[48]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_50" class="kx_ref">[50]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_51" class="kx_ref">[51]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_52" class="kx_ref">[52]</a></sup> 通过x射线晶体学已经确定DES的分子尺寸与雌二醇的分子尺寸几乎相同，特别是分子两端羟基之间的距离。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_52" class="kx_ref">[52]</a></sup> </p></div></div><div id="par_14994946859729414"><h2 class="title">6 历史<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><h3>6.1 <span>合成</span></h3><p></p><p>1938年初，利昂·戈尔堡首次合成了DES，后来他成为了牛津大学戴森·佩林斯实验室罗伯特·罗宾逊爵士的一名研究生。戈尔堡的研究是基于考陶德生物化学研究所的威尔弗里德·劳森的工作（由米德尔塞克斯医院医学院的爱德华·查尔斯·多德爵士领导，米德尔塞克斯医院医学院现在是伦敦大学学院的一部分）。其合成报告于1938年2月5日发表在《自然》杂志上。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_53" class="kx_ref">[53]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_54" class="kx_ref">[54]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_55" class="kx_ref">[55]</a></sup> </p><p>DES研究由英国医学研究委员会（MRC）资助，该委员会制定了一项禁止使用公共资金对发现的药物申请专利的政策。由于没有专利，DES由全球200多家制药和化学公司生产。</p><p></p><h3>6.2 <span>临床应用</span></h3><p></p><p>1941年9月19日，美国食品和药物管理局（FDA）批准了DES（在片剂中最多5毫克）的四种适应症：淋病性阴道炎、萎缩性阴道炎、更年期症状和产后泌乳抑制，以防止乳房充血。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_55" class="kx_ref">[55]</a></sup> 抗生素青霉素上市后，淋病性阴道炎的适应症就取消了。从一开始，这种药物就备受争议。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_56" class="kx_ref">[56]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_57" class="kx_ref">[57]</a></sup> </p><p>1941年，芝加哥大学的查尔斯·哈金斯和克拉伦斯·霍奇斯发现DES是第一种治疗转移性前列腺癌的有效药物。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_58" class="kx_ref">[58]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_59" class="kx_ref">[59]</a></sup> </p><p>睾丸切除术或DES或两者兼顾40多年来症状性晚期前列腺癌的标准初始治疗方法，直到GnRH激动剂亮丙瑞林被发现具有与DES相似的疗效且无雌激素效应，并于1985年获得批准。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_60" class="kx_ref">[60]</a></sup> </p><p>从20世纪40年代到80年代末，DES被美国食品和药物管理局批准作为雌激素缺乏状态（如卵巢发育不良、卵巢早衰和卵巢切除术后）的雌激素替代疗法。</p><p>20世纪40年代，在有流产史的妇女中，DES作为未被临床认可的药物来预防不良妊娠结局。1947年7月1日，美国食品和药物管理局批准将DES应用于这种适应症。首次批准授予百时美施贵宝公司，允许在怀孕期间使用25毫克（后来是100毫克）的DES片剂。同年晚些时候，其他制药公司也获得了批准。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_61" class="kx_ref">[61]</a></sup> 推荐的方案从妊娠第七周和第八周（从末次月经的第一天开始）每天5毫克开始，到第十四周每隔一周增加5毫克，然后从妊娠第十五周的每天25毫克增加到妊娠第三十五周的每天125毫克。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_62" class="kx_ref">[62]</a></sup> DES最初被认为对孕妇和发育中的婴儿都是有效和安全的。它被大力推广，并成为常规处方。销售额在1953年达到顶峰。</p><p>20世纪50年代早期，芝加哥大学的一项双盲临床试验评估了妇女是否给DES药的妊娠结果。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_63" class="kx_ref">[63]</a></sup> 这项研究表明怀孕期间服用DES没有好处；接受DES治疗的妇女的不良妊娠结果没有减少。到了20世纪60年代末，七本主要的产科教科书中有六本称DES在预防流产方面无效。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_61" class="kx_ref">[61]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_64" class="kx_ref">[64]</a></sup> </p><p>尽管没有证据支持使用DES可以预防不良妊娠结局，但DES在20世纪60年代一直被用于孕妇。1971年，发表在《新英格兰医学杂志》上的一份报告显示，在子宫内接触这种药物的女孩和年轻女性中，DES与阴道透明细胞腺癌之间可能存在关联。同年晚些时候，美国食品和药物管理局向所有美国医生发送了一份美国食品和药物管理局药品公告，建议不要在孕妇中使用DES。美国食品和药物管理局还取消了预防流产作为DES使用的适应症，并增加了妊娠作为DES使用的禁忌症。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_65" class="kx_ref">[65]</a></sup> 1975年2月5日，美国食品和药物管理局下令从1975年2月18日起撤回25毫克和100毫克的DES片剂。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_66" class="kx_ref">[66]</a></sup> 1940年至1971年期间，妊娠期或子宫内接触DES的人数不详，但在美国可能高达200万。DES也被应用于其他国家，最显著的是法国、荷兰和英国。</p><p>从20世纪50年代到70年代初，DES被用于即将开始青春期的青春期前女孩，通过关闭骨骼中的生长板来使她们停止生长。尽管这种激素与癌症有明显的联系，但医生们仍继续推荐将这种激素用于“过度长高”。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_67" class="kx_ref">[67]</a></sup> </p><p>1960年，在绝经后妇女晚期乳腺癌的治疗中，DES被认为比雄激素更有效。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_68" class="kx_ref">[68]</a></sup> DES是绝经后妇女晚期乳腺癌的激素治疗选择，直到1977年，美国食品和药物管理局批准了三苯氧胺（他莫昔芬），这是一种选择性雌激素受体调节剂，其疗效与DES相似，但副作用较少。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_69" class="kx_ref">[69]</a></sup> </p><p>20世纪70年代和80年代医学文献的几个来源表明，DES用于治疗变性人。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_70" class="kx_ref">[70]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_71" class="kx_ref">[71]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_72" class="kx_ref">[72]</a></sup> </p><p>1973年，为了将未获得临床许可使用的DES作为如强奸等紧急情况后的性交后避孕方法（在1971年JAMA（美国医学协会）发表了一项有影响力的研究后，这种方法在许多大学卫生服务机构中逐渐普遍），美国食品和药物管理局向所有美国医生和药剂师发送了一份药物公报，称美国食品和药物管理局已在紧急条件下批准使用DES进行性交后避孕。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_73" class="kx_ref">[73]</a></sup> </p><p>1975年，美国食品和药物管理局表示，他们实际上并未批准（也从未批准）任何制造商将DES作为性交后避孕药上市，但如果制造商按照美国食品和药物管理局在1975年最终公布的规定来提供患者标签和特殊包装，它将被批准用于强奸或乱伦等紧急情况适应症。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_74" class="kx_ref">[74]</a></sup> 为了阻止未获得临床许可使用的DES作为性交后避孕药，美国食品和药物管理局于1975年从市场上撤下了DES 25毫克片剂，并下令将仍被批准用于其他适应症的较低剂量（5毫克及以下）的DES适应症改为“该药品不可用作性交后避孕药”，并在医生处方信息包装插页的第一行以及容器和纸箱标签的显著位置用大写印刷体书写。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_66" class="kx_ref">[66]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_75" class="kx_ref">[75]</a></sup> 在20世纪80年代，未获得临床许可的Yuzpe疗法联合某些常规口服避孕药的使用，取代了DES作为性交后避孕药的未获得临床许可使用。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_76" class="kx_ref">[76]</a></sup> </p><p>1978年，美国食品和药物管理局取消了产后哺乳抑制，以防止因为他们批准DES和其他雌激素的适应症而导致的乳房充血。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_77" class="kx_ref">[77]</a></sup> 在20世纪90年代，DES的唯一批准适应症是晚期前列腺癌的治疗和绝经后妇女晚期乳腺癌的治疗。最后一家美国DES制造商礼来公司于1997年停止该药的生产和销售。</p><p></p><h3>6.3 <span>诉讼</span></h3><p></p><p>20世纪70年代，围绕发现DES的长期影响的负面宣传在美国引发了针对其制造商的巨大诉讼浪潮。最终，加州最高法院在1980年做出了一项里程碑式的判决，辛德尔诉雅培实验室案，在该判决中，最高法院对所有DES制造商施加了一项可反驳的市场份额责任推定，其份额与特定原告母亲使用该药时其各自占有的市场份额成比例。</p><p>53名患有乳腺癌的女性向波士顿联邦法院提起诉讼，她们称自己的乳腺癌是母亲在怀孕期间服用DES的结果。他们的案子在道伯特听证会上幸存了下来。2013年，发起乳腺癌/DES链接诉讼的Fecho姐妹在审判的第二天同意支付一笔未披露的和解金额。其余的诉讼当事人已经得到了各种各样的和解。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_78" class="kx_ref">[78]</a></sup> </p></div></div><div id="par_14994946859729415"><h2 class="title">7 社会和文化<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>艾伦·图灵（Alan Turing），开创性的密码学家，计算科学和可编程计算机的创始人，他也提出了生物形态发生的实际理论模型，在死于模棱两可情况的前不久，他被迫服用药物导致化学阉割，作为对同性恋行为的惩罚性“治疗”。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_79" class="kx_ref">[79]</a></sup> </p></div></div><div id="par_14994946859729416"><h2 class="title">8 兽医用途<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><h3>8.1 <span>犬失禁</span></h3><p></p><p>DES在治疗因括约肌控制不良引起的雌犬失禁方面非常成功。它仍然可以从药房买到，并且在低剂量（1毫克）下，不具有像对人类那样大的致癌特性。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_80" class="kx_ref">[80]</a></sup> 通常每天给药一次，持续7-10天，然后根据需要每周给药一次。</p><p></p><h3>8.2 <span>牲畜生长促进</span></h3><p></p><p>DES的最大用途是在畜牧业，用于改善牛肉和家禽的饲料转化率。在20世纪60年代，DES被用作牛肉和家禽行业的生长激素。后来在1971年，发现它会导致癌症，但直到1979年才被逐步淘汰。<sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_81" class="kx_ref">[81]</a></sup><sup><a href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/d10120.htm#quote_82" class="kx_ref">[82]</a></sup> 当发现DES对人类有害时，它被转移到兽医上使用。</p></div></div></div></div><div id="references"><h2 class="title" id="par_references">参考文献</h2><ul class="references"><li id="quote_1"><span class="references-num">[1]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 396–. ISBN 978-1-4757-2085-3..</span></p></li><li id="quote_2"><span class="references-num">[2]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Veurink M, Koster M, Berg LT (June 2005). "The history of DES, lessons to be learned". Pharm World Sci. 27 (3): 139–43. doi:10.1007/s11096-005-3663-z. PMID 16096877..</span></p></li><li id="quote_3"><span class="references-num">[3]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"DES Update: For Consumers". United States Department of Health and Human Services: Centers for Disease Control and Prevention. Retrieved 2011-06-30..</span></p></li><li id="quote_4"><span class="references-num">[4]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"DES: Questions and Answers". FactSheet. National Cancer Institute. Retrieved 2011-06-30..</span></p></li><li id="quote_5"><span class="references-num">[5]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Arnold, Amanda (January 5, 2017). "The Devastating Effects of a 1940s 'Wonder Pill' Haunt Women Generations Later". Broadly..</span></p></li><li id="quote_6"><span class="references-num">[6]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Coelingh Bennink HJ (April 2004). "Are all estrogens the same?". Maturitas. 47 (4): 269–75. doi:10.1016/j.maturitas.2003.11.009. PMID 15063479..</span></p></li><li id="quote_7"><span class="references-num">[7]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Noller KL, Fish CR (July 1974). "Diethylstilbestrol usage: Its interesting past, important present, and questionable future". Med. Clin. North Am. 58 (4): 793–810. doi:10.1016/S0025-7125(16)32122-8. PMID 4276416..</span></p></li><li id="quote_8"><span class="references-num">[8]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Thompson IM (2001). "Flare Associated with LHRH-Agonist Therapy". Rev Urol. 3 Suppl 3: S10–4. PMC 1476081. PMID 16986003..</span></p></li><li id="quote_9"><span class="references-num">[9]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Scaletscky R, Smith JA (April 1993). "Disease flare with gonadotrophin-releasing hormone (GnRH) analogues. How serious is it?". Drug Saf. 8 (4): 265–70. doi:10.2165/00002018-199308040-00001. PMID 8481213..</span></p></li><li id="quote_10"><span class="references-num">[10]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kreis W, Ahmann FR, Jordan VC, de Haan H, Scott M (October 1988). "Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation". Br J Urol. 62 (4): 352–4. doi:10.1111/j.1464-410X.1988.tb04364.x. PMID 2973364..</span></p></li><li id="quote_11"><span class="references-num">[11]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Stein BS, Smith JA (April 1985). "DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate". Urology. 25 (4): 350–3. doi:10.1016/0090-4295(85)90484-4. PMID 3920802..</span></p></li><li id="quote_12"><span class="references-num">[12]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Fernandez del Moral P, Litjens TT, Weil EH, Debruyne FM (August 1988). "Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?". Urology. 32 (2): 137–40. doi:10.1016/0090-4295(88)90316-0. PMID 2969641..</span></p></li><li id="quote_13"><span class="references-num">[13]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bruchovsky N, Goldenberg SL, Akakura K, Rennie PS (September 1993). "Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol". Cancer. 72 (5): 1685–91. doi:10.1002/1097-0142(19930901)72:5&lt;1685::AID-CNCR2820720532&gt;3.0.CO;2-3. PMID 7688656..</span></p></li><li id="quote_14"><span class="references-num">[14]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kotake T, Usami M, Akaza H, Koiso K, Homma Y, Kawabe K, Aso Y, Orikasa S, Shimazaki J, Isaka S, Yoshida O, Hirao Y, Okajima E, Naito S, Kumazawa J, Kanetake H, Saito Y, Ohi Y, Ohashi Y (November 1999). "Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group". Jpn. J. Clin. Oncol. 29 (11): 562–70. doi:10.1093/jjco/29.11.562. PMID 10678560..</span></p></li><li id="quote_15"><span class="references-num">[15]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Reis LO, Zani EL, García-Perdomo HA (June 2018). "Estrogen therapy in patients with prostate cancer: a contemporary systematic review". Int Urol Nephrol. 50 (6): 993–1003. doi:10.1007/s11255-018-1854-5. PMID 29600433..</span></p></li><li id="quote_16"><span class="references-num">[16]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bosset PO, Albiges L, Seisen T, de la Motte Rouge T, Phé V, Bitker MO, Rouprêt M (December 2012). "Current role of diethylstilbestrol in the management of advanced prostate cancer". BJU Int. 110 (11 Pt C): E826–9. doi:10.1111/j.1464-410X.2012.11206.x. PMID 22578092..</span></p></li><li id="quote_17"><span class="references-num">[17]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Scherr DS, Pitts WR (November 2003). "The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer". J. Urol. 170 (5): 1703–8. doi:10.1097/01.ju.0000077558.48257.3d. PMID 14532759..</span></p></li><li id="quote_18"><span class="references-num">[18]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Oh WK (September 2002). "The evolving role of estrogen therapy in prostate cancer". Clin Prostate Cancer. 1 (2): 81–9. PMID 15046698..</span></p></li><li id="quote_19"><span class="references-num">[19]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Malkowicz SB (August 2001). "The role of diethylstilbestrol in the treatment of prostate cancer". Urology. 58 (2 Suppl 1): 108–13. PMID 11502463..</span></p></li><li id="quote_20"><span class="references-num">[20]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Cox RL, Crawford ED (December 1995). "Estrogens in the treatment of prostate cancer". J. Urol. 154 (6): 1991–8. PMID 7500443..</span></p></li><li id="quote_21"><span class="references-num">[21]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Lycette JL, Bland LB, Garzotto M, Beer TM (December 2006). "Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?". Clin Genitourin Cancer. 5 (3): 198–205. doi:10.3816/CGC.2006.n.037. PMID 17239273..</span></p></li><li id="quote_22"><span class="references-num">[22]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Marselos M, Tomatis L (1992). "Diethylstilboestrol: I, Pharmacology, Toxicology and carcinogenicity in humans". Eur. J. Cancer. 28A (6–7): 1182–9. PMID 1627392..</span></p></li><li id="quote_23"><span class="references-num">[23]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ellis, MJ; Dehdahti, F; Kommareddy, A; Jamalabadi-Majidi, S; Crowder, R; Jeffe, DB; Gao, F; Fleming, G; Silverman, P; Dickler, M; Carey, L; Marcom, PK (2014). "A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer". Cancer Research. 69 (2 Supplement): 16. doi:10.1158/0008-5472.SABCS-16. ISSN 0008-5472..</span></p></li><li id="quote_24"><span class="references-num">[24]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Swyer GI (April 1959). "The oestrogens". Br Med J. 1 (5128): 1029–31. doi:10.1136/bmj.1.5128.1029. PMC 1993181. PMID 13638626. [Diethylstilbestrol] suffers from the serious drawback that in doses above 1 mg. a day it is likely to produce nausea, vomiting, abdominal discomfort, headache, and bloating in a proportion of patients varyingly estimated from 15 to 50%..</span></p></li><li id="quote_25"><span class="references-num">[25]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Phillips I, Shah SI, Duong T, Abel P, Langley RE (2014). "Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer". Oncol Hematol Rev. 10 (1): 42–47. PMC 4052190. PMID 24932461..</span></p></li><li id="quote_26"><span class="references-num">[26]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Di Lorenzo G, Autorino R, Perdonà S, De Placido S (December 2005). "Management of gynaecomastia in patients with prostate cancer: a systematic review". Lancet Oncol. 6 (12): 972–9. doi:10.1016/S1470-2045(05)70464-2. PMID 16321765..</span></p></li><li id="quote_27"><span class="references-num">[27]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bamigboye AA, Morris J (2003). "Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes". Cochrane Database Syst Rev (3): CD004353. doi:10.1002/14651858.CD004353. PMID 12918007..</span></p></li><li id="quote_28"><span class="references-num">[28]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Coelingh Bennink HJ, Verhoeven C, Dutman AE, Thijssen J (January 2017). "The use of high-dose estrogens for the treatment of breast cancer". Maturitas. 95: 11–23. doi:10.1016/j.maturitas.2016.10.010. PMID 27889048..</span></p></li><li id="quote_29"><span class="references-num">[29]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Jordan VC (2013). Estrogen Action, Selective Estrogen Receptor Modulators, and Women's Health: Progress and Promise. World Scientific. pp. 143–. ISBN 978-1-84816-958-6..</span></p></li><li id="quote_30"><span class="references-num">[30]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Seiler JP, Autrup JL, Autrup H (6 December 2012). Diversification in Toxicology — Man and Environment: Proceedings of the 1997 EUROTOX Congress Meeting Held in Århus, Denmark, June 25–28, 1997. Springer Science &amp; Business Media. pp. 23–. ISBN 978-3-642-46856-8..</span></p></li><li id="quote_31"><span class="references-num">[31]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA (March 1997). "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta". Endocrinology. 138 (3): 863–70. doi:10.1210/endo.138.3.4979. PMID 9048584..</span></p></li><li id="quote_32"><span class="references-num">[32]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Coss CC, Jones A, Parke DN, Narayanan R, Barrett CM, Kearbey JD, Veverka KA, Miller DD, Morton RA, Steiner MS, Dalton JT (March 2012). "Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer". Endocrinology. 153 (3): 1070–81. doi:10.1210/en.2011-1608. PMID 22294742..</span></p></li><li id="quote_33"><span class="references-num">[33]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bruce Chabner; Dan Louis Longo (1996). Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott-Raven Publishers. p. 186. ISBN 978-0-397-51418-2. Piperazine estrone sulfate and micronized estradiol were equipotent with respect to increases in SHBG, whereas [...] DES was 28.4-fold more potent [...]. With respect to decreased FSH, [...] DES was 3.8-fold, and ethinyl estradiol was 80 to 200-fold more potent than was piperazine estrone sulfate. The dose equivalents for ethinyl estradiol (50 µg) and DES (1 mg) reflect these relative potencies.220 [...] DES, a potent synthetic estrogen (Fig. 6-12), is absorbed well after an oral dosage. Patients given 1 mg of DES daily had plasma concentrations at 20 hours ranging from 0.9 to 1.9 ng per mL. The initial half-life of DES is 80 minutes, with a secondary half-life of 24 hours.222 The principal pathways of metabolism are conversion to the glucuronide and oxidation. The oxidative pathways include aromatic hydroxylation of the ethyl side chains and dehydrogenation to (Z,Z)-dienestrol, producing transient quinone-like intermediates that react with cellular macromolecules and cause genetic damage in eukaryotic cells.223 Metabolic activation of DES may explain its well-established carcinogenic properties.224.</span></p></li><li id="quote_34"><span class="references-num">[34]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947..</span></p></li><li id="quote_35"><span class="references-num">[35]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Benno Runnebaum; Thomas Rabe (17 April 2013). Gynäkologische Endokrinologie und Fortpflanzungsmedizin: Band 1: Gynäkologische Endokrinologie. Springer-Verlag. pp. 88–. ISBN 978-3-662-07635-4..</span></p></li><li id="quote_36"><span class="references-num">[36]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer". Cancer. 45 Suppl 7: 1929–1936. doi:10.1002/cncr.1980.45.s7.1929. PMID 29603164..</span></p></li><li id="quote_37"><span class="references-num">[37]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Muhammad A. Salam (2003). Principles &amp; Practice of Urology: A Comprehensive Text. Universal-Publishers. pp. 684–. ISBN 978-1-58112-412-5..</span></p></li><li id="quote_38"><span class="references-num">[38]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS (January 2006). "Secondary hormonal therapy for advanced prostate cancer". J. Urol. 175 (1): 27–34. doi:10.1016/S0022-5347(05)00034-0. PMID 16406864..</span></p></li><li id="quote_39"><span class="references-num">[39]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Turo R, Smolski M, Esler R, Kujawa ML, Bromage SJ, Oakley N, Adeyoju A, Brown SC, Brough R, Sinclair A, Collins GN (February 2014). "Diethylstilboestrol for the treatment of prostate cancer: past, present and future". Scand J Urol. 48 (1): 4–14. doi:10.3109/21681805.2013.861508. PMID 24256023..</span></p></li><li id="quote_40"><span class="references-num">[40]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CM (December 1988). "The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma". J. Urol. 140 (6): 1460–5. doi:10.1016/S0022-5347(17)42073-8. PMID 2973529..</span></p></li><li id="quote_41"><span class="references-num">[41]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD (June 1996). "Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration". Urology. 47 (6): 882–4. doi:10.1016/S0090-4295(96)00048-9. PMID 8677581..</span></p></li><li id="quote_42"><span class="references-num">[42]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Greschik H, Flaig R, Renaud JP, Moras D (August 2004). "Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity". The Journal of Biological Chemistry. 279 (32): 33639–46. doi:10.1074/jbc.M402195200. PMID 15161930..</span></p></li><li id="quote_43"><span class="references-num">[43]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Pugeat MM, Dunn JF, Nisula BC (July 1981). "Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma". J. Clin. Endocrinol. Metab. 53 (1): 69–75. doi:10.1210/jcem-53-1-69. PMID 7195405..</span></p></li><li id="quote_44"><span class="references-num">[44]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Oelschläger, Herbert; Rothley, Dietrich; Dunzendorfer, Udo (1988). "New Results on the Pharmacokinetics of Fosfestrol". Urologia Internationalis. 43 (1): 15–23. doi:10.1159/000281427. ISSN 1423-0399..</span></p></li><li id="quote_45"><span class="references-num">[45]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Droz JP, Kattan J, Bonnay M, Chraibi Y, Bekradda M, Culine S (February 1993). "High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancer". Cancer. 71 (3 Suppl): 1123–30. doi:10.1002/1097-0142(19930201)71:3+&lt;1123::AID-CNCR2820711434&gt;3.0.CO;2-T. PMID 8428334..</span></p></li><li id="quote_46"><span class="references-num">[46]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Chambers P, Günzel P (12 March 2013). Mechanism of Toxic Action on Some Target Organs: Drugs and Other Substances. Springer Science &amp; Business Media. pp. 276–. ISBN 978-3-642-67265-1..</span></p></li><li id="quote_47"><span class="references-num">[47]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Couse JF, Korach KS (December 2004). "Estrogen receptor-alpha mediates the detrimental effects of neonatal diethylstilbestrol (DES) exposure in the murine reproductive tract". Toxicology. 205 (1–2): 55–63. doi:10.1016/j.tox.2004.06.046. PMID 15458790..</span></p></li><li id="quote_48"><span class="references-num">[48]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Vitamins and Hormones. Academic Press. 1945. pp. 233–. ISBN 978-0-08-086600-0..</span></p></li><li id="quote_49"><span class="references-num">[49]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Camille Georges Wermuth; David Aldous; Pierre Raboisson; Didier Rognan (1 July 2015). The Practice of Medicinal Chemistry. Elsevier Science. pp. 244–245. ISBN 978-0-12-417213-5..</span></p></li><li id="quote_50"><span class="references-num">[50]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Maximov PY, McDaniel RE, Jordan VC (23 July 2013). Tamoxifen: Pioneering Medicine in Breast Cancer. Springer Science &amp; Business Media. pp. 3–. ISBN 978-3-0348-0664-0..</span></p></li><li id="quote_51"><span class="references-num">[51]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ravina E (11 January 2011). T he Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley &amp; Sons. pp. 177–. ISBN 978-3-527-32669-3..</span></p></li><li id="quote_52"><span class="references-num">[52]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Sneader W (31 October 2005). Drug Discovery: A History. John Wiley &amp; Sons. pp. 196–197. ISBN 978-0-470-01552-0..</span></p></li><li id="quote_53"><span class="references-num">[53]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Dodds EC, Goldberg L, Lawson W, Robinson R (1938). "Estrogenic activity of certain synthetic compounds". Nature. 141 (3562): 247–8. doi:10.1038/141247b0..</span></p></li><li id="quote_54"><span class="references-num">[54]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Dodds EC (1957). Biochemical contributions to endocrinology; experiments in hormonal research. Stanford: Stanford University Press. OCLC 1483899..</span></p></li><li id="quote_55"><span class="references-num">[55]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Meyers R (1983). D.E.S., the bitter pill. New York: Seaview/Putnam. ISBN 0-399-31008-8..</span></p></li><li id="quote_56"><span class="references-num">[56]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Langston N (2010). Toxic bodies: Hormone disruptors and the legacy of DES. New Haven, CT: Yale University Press. ISBN 978-0-300-13607-4..</span></p></li><li id="quote_57"><span class="references-num">[57]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Seaman B (2003). The greatest experiment ever performed on women: Exploding the estrogen myth. New York: Hyperion. ISBN 978-0-7868-6853-7..</span></p></li><li id="quote_58"><span class="references-num">[58]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Huggins C, Hodges CV (1972). "Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate". CA. 22 (4): 232–40. doi:10.3322/canjclin.22.4.232. PMID 4625049..</span></p></li><li id="quote_59"><span class="references-num">[59]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Prostate cancer yields to a drug". The New York Times. 15 December 1943. p. 29..</span></p></li><li id="quote_60"><span class="references-num">[60]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">The Leuprolide Study Group (November 1984). "Leuprolide versus diethylstilbestrol for metastatic prostate cancer". The New England Journal of Medicine. 311 (20): 1281–6. doi:10.1056/NEJM198411153112004. PMID 6436700..</span></p></li><li id="quote_61"><span class="references-num">[61]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Dutton DB (1988). Worse than the disease: pitfalls of medical progress. Cambridge: Cambridge University Press. ISBN 0-521-34023-3..</span></p></li><li id="quote_62"><span class="references-num">[62]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Physicians' desk reference to pharmaceutical specialties and biologicals (15th ed.). Oradell NJ: Medical Economics. 1961. p. 625. ISBN 0-00-093447-X..</span></p></li><li id="quote_63"><span class="references-num">[63]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Dieckmann WJ, Davis ME, Rynkiewicz LM, Pottinger RE (November 1953). "Does the administration of diethylstilbestrol during pregnancy have therapeutic value?". American Journal of Obstetrics and Gynecology. 66 (5): 1062–81. doi:10.1016/S0002-9378(16)38617-3. PMID 13104505..</span></p></li><li id="quote_64"><span class="references-num">[64]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Apfel RJ, Fisher SM (1984). To do no harm: DES and the dilemmas of modern medicine. New Haven: Yale University Press. ISBN 0-300-03192-0..</span></p></li><li id="quote_65"><span class="references-num">[65]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">United States Food and Drug Administration (1971). "Certain estrogens for oral or parenteral use. Drugs for human use; drug efficacy study implementation". Fed Regist. 36 (217): 21537–8.; 36 FR 21537.</span></p></li><li id="quote_66"><span class="references-num">[66]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">FDA (1975). "Certain estrogens for oral use. Notice of withdrawal of approval of new drug applications". Fed Regist. 40 (25): 5384.; 25 FR 5384.</span></p></li><li id="quote_67"><span class="references-num">[67]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Zuger A (2009-07-27). "At What Height, Happiness? A Medical Tale". The New York Times. NY Times..</span></p></li><li id="quote_68"><span class="references-num">[68]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Council on Drugs (1960). "Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients". JAMA. 172 (12): 1271–83. doi:10.1001/jama.1960.03020120049010..</span></p></li><li id="quote_69"><span class="references-num">[69]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S (January 1981). "Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer". The New England Journal of Medicine. 304 (1): 16–21. doi:10.1056/NEJM198101013040104. PMID 7001242..</span></p></li><li id="quote_70"><span class="references-num">[70]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Goodwin WE, Cummings RH (March 1984). "Squamous metaplasia of the verumontanum with obstruction due to hypertrophy: long-term effects of estrogen on the prostate in an aging male-to-female transsexual". The Journal of Urology. 131 (3): 553–4. doi:10.1016/s0022-5347(17)50493-0. PMID 6199525..</span></p></li><li id="quote_71"><span class="references-num">[71]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Lehrman KL (February 1976). "Pulmonary embolism in a transsexual man taking diethylstilbestrol". JAMA. 235 (5): 532–3. doi:10.1001/jama.1976.03260310046024. PMID 946104..</span></p></li><li id="quote_72"><span class="references-num">[72]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Seyler LE, Canalis E, Spare S, Reichlin S (July 1978). "Abnormal gonadotropin secretory responses to LRH in transsexual women after diethylstilbestrol priming". The Journal of Clinical Endocrinology and Metabolism. 47 (1): 176–83. doi:10.1210/jcem-47-1-176. PMID 122396..</span></p></li><li id="quote_73"><span class="references-num">[73]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kuchera LK (October 1971). "Postcoital contraception with diethylstilbestrol". JAMA. 218 (4): 562–3. doi:10.1001/jama.218.4.562. PMID 5171004..</span></p></li><li id="quote_74"><span class="references-num">[74]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">FDA (1975). "Diethylstilbestrol as posticoital oral contraceptive; patient labeling". Fed Regist. 40 (25): 5451–5.; 40 FR 5451.</span></p></li><li id="quote_75"><span class="references-num">[75]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">FDA (1975). "Estrogens for oral or parenteral use. Drugs for human use; drug efficacy study; amended notice". Fed Regist. 40 (39): 8242.; 39 FR 8242.</span></p></li><li id="quote_76"><span class="references-num">[76]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Hatcher RA, Stewart GK, Stewart F, Guest F, Josephs N, Dale J (1982). Contraceptive Technology 1982–1983. New York: Irvington Publishers. pp. 152–7. ISBN 0-8290-0705-9..</span></p></li><li id="quote_77"><span class="references-num">[77]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">FDA (1978). "Estrogens for postpartum breast engorgement". Fed Regist. 43 (206): 49564–7.; 43 FR 49564.</span></p></li><li id="quote_78"><span class="references-num">[78]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Lavoie D (9 January 2013). "DES Pregnancy Drug Lawsuit: Settlement Reached Between Melnick Sisters And Eli Lilly And Co". Huffington Post. Archived from the original on 10 January 2013. Retrieved 19 March 2014..</span></p></li><li id="quote_79"><span class="references-num">[79]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">West-Taylor Z. "The Alan Turing Law – a Formal Pardon for Unpardonable Homophobia". Affinity magazine. Retrieved 3 December 2016..</span></p></li><li id="quote_80"><span class="references-num">[80]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Urinary Incontinence". Merck Veterinary Manual. Merck Veterinary Manual. Retrieved 30 November 2012..</span></p></li><li id="quote_81"><span class="references-num">[81]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Harris RM, Waring RH (June 2012). "Diethylstilboestrol--a long-term legacy". Maturitas. 72 (2): 108–12. doi:10.1016/j.maturitas.2012.03.002. PMID 22464649..</span></p></li><li id="quote_82"><span class="references-num">[82]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Gandhi R, Snedeker S (2000-06-01). "Consumer Concerns About Hormones in Food". Fact Sheet #37, June 2000. Program on Breast Cancer and Environmental Risk Factors, Cornell University. Archived from the original on 2011-07-19. Retrieved 2011-07-20..</span></p></li></ul></div><div class="read-num">阅读 <!-- -->2575</div></div><div class="right-side" id="rightSide"><div class="side" id="lemma-side"><div class="side-title">版本记录</div><ul class="side-lst"><li><p class="side-lst-txt">暂无</p></li></ul><div class="user-card userCard"></div></div><div class="side"><div class="side-event"></div></div></div></div><div class="footer-box"><div id="footer"><div class="footer-logo-wrap"><div class="footer-logo"></div><div class="footer-logo-text">知识·传播·科普</div></div><div class="footer-info">本网站内容采用<a target="_blank" href="https://web.archive.org/web/20221029032313/https://creativecommons.org/licenses/by-sa/3.0/deed.zh?tdsourcetag=s_pctim_aiomsg">CC-BY-SA 3.0</a>授权</div><div class="footer-btn-wrap"><a target="_blank" href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/help/#user_protocol">用户协议</a><a target="_blank" href="https://web.archive.org/web/20221029032313/http://www.sogou.com/docs/terms.htm?v=1">免责声明</a><a target="_blank" href="https://web.archive.org/web/20221029032313/http://corp.sogou.com/private.html">隐私政策</a><a target="_blank" href="https://web.archive.org/web/20221029032313/https://baike.sogou.com/kexue/intro.htm">关于我们</a></div></div></div><script>window.lemmaInfo ={"lemmaId":"10120","versionId":"52068869845600263","title":"己烯雌酚","subtitle":"","abstracts":{"paragraphId":"51190979050383111","title":"摘要","versionId":"52068869845600264","lemmaId":10120,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598331464,"comment":null,"dependVersionId":0,"contentType":2,"content":"<p>己烯雌酚（DES），也称为苯乙烯雌酚，是一种雌激素药物，但现已几乎不再使用。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup> 过去，它被广泛用于各种适应症，包括对有反复流产史的妇女的妊娠支持、对妇女更年期症状和雌激素缺乏的激素治疗、对男性前列腺癌和女性乳腺癌的治疗以及其他用途。虽然口服给药最常见，但也可通过其他途径使用，如阴道给药、局部给药和注射给药。</p>\n<p>DES是雌激素或雌激素受体的激动剂，是雌二醇等雌激素的生物学靶点。 它是芪类合成的非甾体雌激素，在各方面均不同于天然雌激素雌二醇。 与雌二醇相比，口服DES大大提高了生物利用度，更能抵抗新陈代谢，并在身体的某些部位（如肝脏和子宫）显示出相对增强的效果。 这些差异导致DES在血栓、心血管问题和某些其他副作用上的风险增加。</p>\n<p>DES于1938年被发现。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> 从1940年到1971年，这种药物被用来给孕妇服用，并被错误地认为会降低妊娠并发症和流产的风险。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> 1971年，人们发现DES能够在子宫内接触过这种药物的女孩和妇女中引起透明细胞癌，这是一种罕见的阴道肿瘤。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> 随后，美国食品和药物管理局撤销了对DES作为孕妇治疗方法的批准。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> 后续研究表明，DES也有可能在接触者的生命周期内引起各种严重的不良医疗并发症。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup><sup><a href=\"#quote_3\" class=\"kx_ref\">[3]</a></sup> </p>\n<p>美国国家癌症研究所建议<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup> 服用过DES的婴儿母亲定期接受特殊医学检查，以筛查药物治疗引起的并发症。母亲怀孕期间接触DES的人通常被称为“DES女儿”和“DES儿子”。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup><sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup> 自从发现DES的毒性作用后，它基本上已经停止使用，现在基本上不再投入市场。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup><sup><a href=\"#quote_6\" class=\"kx_ref\">[6]</a></sup> </p>","pics":[{"originalUrl":"https://web.archive.org/web/20221029032313/https://img03.sogoucdn.com/app/a/200698/1080_474_20200819113542-273547600.jpg?width=231&height=174&titlename=%E5%B7%B1%E7%83%AF%E9%9B%8C%E9%85%9A%E5%88%86%E5%AD%90%E5%BC%8F&w=1080&h=474","url":"https://web.archive.org/web/20221029032313/https://img03.sogoucdn.com/app/a/200698/1080_474_20200819113542-273547600.jpg","rw":1080,"rh":474,"title":"己烯雌酚分子式","alt":null,"width":231,"height":174}],"card":null,"references":[],"versionCount":0},"card":{"paragraphId":"0","title":"","versionId":"0","lemmaId":0,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":0,"comment":null,"dependVersionId":0,"contentType":0,"content":"","pics":null,"card":null,"references":null,"versionCount":0},"categories":[{"id":3,"name":"化学","parents":[]}],"creator":{"uid":76038055,"name":"卤蛋","pic":"https://web.archive.org/web/20221029032313/https://cache.soso.com/qlogo/g?b=oidb&k=8Ak2ibxiaZIqGAqKxiao3ib0Pg&s=100&t=1555105652","introduction":null,"educations":[{"schoolName":"南昌大学","major":"","degree":"硕士","universityId":69,"universityLogo":"https://web.archive.org/web/20221029032313/https://img01.sogoucdn.com/app/a/200943/1aa589fe-6012-11e9-a2ef-fc4dd4f70029","majorLevel1":"理学","majorLevel2":"化学","majorLevel3":"化学","majorLevel1Id":1,"majorLevel2Id":63,"majorLevel3Id":68,"state":null,"lab":null,"researchField":null}],"jobs":null,"works":null,"educationBrief":"南昌大学","jobBrief":"","role":0,"roleName":null,"title":"南昌大学 · 化学硕士","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":72,"partnerIdCreateTime":1594286508,"partnerIdPoped":false},"createTime":1571038216,"editor":{"uid":81910391,"name":"是福不是祸","pic":"https://web.archive.org/web/20221029032313/https://cache.soso.com/qlogo/g?b=oidb&k=6iaUd8ybMyWyTRyUPWibRsLg&s=100&t=1566664174","introduction":"全幼儿园最可爱的小朋友","educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":"","phoneNo":null,"editable":true,"partnerId":236,"partnerIdCreateTime":1596529271,"partnerIdPoped":true},"editTime":1598331464,"state":1,"versionCount":4,"upNum":1,"downNum":0,"pics":[{"originalUrl":"https://web.archive.org/web/20221029032313/https://img03.sogoucdn.com/app/a/200698/1080_474_20200819113542-273547600.jpg?width=231&height=174&titlename=%E5%B7%B1%E7%83%AF%E9%9B%8C%E9%85%9A%E5%88%86%E5%AD%90%E5%BC%8F&w=1080&h=474","url":"https://web.archive.org/web/20221029032313/https://img03.sogoucdn.com/app/a/200698/1080_474_20200819113542-273547600.jpg","rw":1080,"rh":474,"title":"己烯雌酚分子式","alt":null,"width":231,"height":174},{"originalUrl":"https://web.archive.org/web/20221029032313/https://img03.sogoucdn.com/app/a/200698/sogou_science_1048?w=265&h=324&titlename=%E9%9B%8C%E4%BA%8C%E9%86%87%E5%92%8CDES%E7%9A%84%E5%8C%96%E5%AD%A6%E7%BB%93%E6%9E%84%E3%80%82%5B1%5D%20%E6%B3%A8%E6%84%8FDES%E4%B8%AD%E5%AD%98%E5%9C%A8%E4%B8%A4%E4%B8%AA%E7%BE%9F%E5%9F%BA%EF%BC%8C%E5%AE%83%E4%BB%AC%E4%B9%8B%E9%97%B4%E7%9A%84%E8%B7%9D%E7%A6%BB%E4%B8%8E%E9%9B%8C%E4%BA%8C%E9%86%87%E4%B8%A4%E4%B8%AA%E7%BE%9F%E5%9F%BA%E4%B9%8B%E9%97%B4%E7%9A%84%E8%B7%9D%E7%A6%BB%E7%9B%B8%E4%BC%BC%EF%BC%8C%E5%BD%93%E8%AE%A4%E4%B8%BADES%E6%98%AF%E8%A2%AB%E5%81%B6%E7%84%B6%E5%8F%91%E7%8E%B0%E7%9A%84%E6%97%B6%E5%80%99%EF%BC%8C%E8%BF%99%E4%B8%80%E7%82%B9%E5%80%BC%E5%BE%97%E6%B3%A8%E6%84%8F%E3%80%82%5B1%5D%5B2%5D%5B3%5D","url":"https://web.archive.org/web/20221029032313/https://img03.sogoucdn.com/app/a/200698/sogou_science_1048","rw":265,"rh":324,"title":"雌二醇和DES的化学结构。[1] 注意DES中存在两个羟基，它们之间的距离与雌二醇两个羟基之间的距离相似，当认为DES是被偶然发现的时候，这一点值得注意。[1][2][3]","alt":null,"width":0,"height":0}],"catalogs":[{"level":1,"title":"医疗用途","paragraphId":"14994946826174978","subCatalogs":null},{"level":1,"title":"副作用","paragraphId":"14994946826174979","subCatalogs":[{"level":2,"title":"长期影响","paragraphId":"14994946826174979","subCatalogs":null}]},{"level":1,"title":"用药过量","paragraphId":"14994946842952194","subCatalogs":null},{"level":1,"title":"药理学","paragraphId":"14994946842952195","subCatalogs":[{"level":2,"title":"药效学","paragraphId":"14994946842952195","subCatalogs":null},{"level":2,"title":"药代动力学","paragraphId":"14994946842952195","subCatalogs":null}]},{"level":1,"title":"化学","paragraphId":"14994946842952196","subCatalogs":null},{"level":1,"title":"历史","paragraphId":"14994946859729414","subCatalogs":[{"level":2,"title":"合成","paragraphId":"14994946859729414","subCatalogs":null},{"level":2,"title":"临床应用","paragraphId":"14994946859729414","subCatalogs":null},{"level":2,"title":"诉讼","paragraphId":"14994946859729414","subCatalogs":null}]},{"level":1,"title":"社会和文化","paragraphId":"14994946859729415","subCatalogs":null},{"level":1,"title":"兽医用途","paragraphId":"14994946859729416","subCatalogs":[{"level":2,"title":"犬失禁","paragraphId":"14994946859729416","subCatalogs":null},{"level":2,"title":"牲畜生长促进","paragraphId":"14994946859729416","subCatalogs":null}]},{"level":1,"title":"参考文献","paragraphId":"-1","subCatalogs":null}],"paragraphs":[{"paragraphId":"14994946826174978","title":"医疗用途","versionId":"52068869845600265","lemmaId":10120,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598331464,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>DES在过去被用于以下适应症：<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> </p><p>\n <ul>\n  <li>怀孕期间反复流产</li>\n  <li>更年期激素疗法，用于治疗更年期症状，如热潮红和阴道萎缩</li>\n  <li>雌激素过少症的激素治疗（例如性腺发育不良、卵巢早衰和卵巢切除术后）</li>\n  <li>抑制产后泌乳以防止或逆转乳房充血</li>\n  <li>淋病性阴道炎（抗生素青霉素采用后停用）</li>\n  <li>前列腺癌和乳腺癌</li>\n  <li>青春期女孩身材高大的预防</li>\n  <li>作为性交后的紧急避孕药</li>\n  <li>作为化学阉割的一种手段，用于男性性欲亢进和性欲倒错以及性犯罪者促性腺激素释放激素</li>\n  <li>在促性腺激素释放激素激动剂（GnRH激动剂）疗法开始时抑制睾丸激素升高<sup><a href=\"#quote_8\" class=\"kx_ref\">[8]</a></sup><sup><a href=\"#quote_9\" class=\"kx_ref\">[9]</a></sup><sup><a href=\"#quote_10\" class=\"kx_ref\">[10]</a></sup><sup><a href=\"#quote_11\" class=\"kx_ref\">[11]</a></sup><sup><a href=\"#quote_12\" class=\"kx_ref\">[12]</a></sup><sup><a href=\"#quote_13\" class=\"kx_ref\">[13]</a></sup><sup><a href=\"#quote_14\" class=\"kx_ref\">[14]</a></sup></li>\n </ul></p><p>人们对使用DES治疗男性前列腺癌的兴趣一直持续到今天。<sup><a href=\"#quote_15\" class=\"kx_ref\">[15]</a></sup><sup><a href=\"#quote_16\" class=\"kx_ref\">[16]</a></sup><sup><a href=\"#quote_17\" class=\"kx_ref\">[17]</a></sup><sup><a href=\"#quote_18\" class=\"kx_ref\">[18]</a></sup><sup><a href=\"#quote_19\" class=\"kx_ref\">[19]</a></sup><sup><a href=\"#quote_20\" class=\"kx_ref\">[20]</a></sup> 然而，一些研究人员主张使用生物识别的胃肠外雌激素，如聚乙二醇磷酸酯，而不是口服合成雌激素，如DES，因为它们的心血管毒性风险低得多。<sup><a href=\"#quote_21\" class=\"kx_ref\">[21]</a></sup><sup><a href=\"#quote_18\" class=\"kx_ref\">[18]</a></sup><sup><a href=\"#quote_20\" class=\"kx_ref\">[20]</a></sup> 除了前列腺癌之外，人们对使用DES治疗女性乳腺癌的兴趣也持续到今天。<sup><a href=\"#quote_22\" class=\"kx_ref\">[22]</a></sup> 然而，与前列腺癌的情况相似，一些研究人员主张使用生物识别雌激素，如雌二醇，而不是DES，来治疗乳腺癌。<sup><a href=\"#quote_23\" class=\"kx_ref\">[23]</a></sup> </p><p>\n <table class=\"wikitable\">\n  <tbody>\n   <tr>\n    <td colspan=\"3\">雌激素用于乳腺癌的剂量</td>\n   </tr>\n   <tr>\n    <td>路径/形式</td>\n    <td>雌激素</td>\n    <td>剂量</td>\n   </tr>\n   <tr>\n    <td rowspan=\"6\">口服</td>\n    <td>雌二醇</td>\n    <td>10毫克3次/天<p>抗AI：2毫克1-3次/天</p></td>\n   </tr>\n   <tr>\n    <td>雌二醇戊酸酯</td>\n    <td>抗AI：2毫克1-3次/天</td>\n   </tr>\n   <tr>\n    <td>共轭雌激素</td>\n    <td>10毫克3次/天</td>\n   </tr>\n   <tr>\n    <td>炔雌醇</td>\n    <td>0.5–1毫克3次/天</td>\n   </tr>\n   <tr>\n    <td>己烯雌酚</td>\n    <td>5毫克3次/天</td>\n   </tr>\n   <tr>\n    <td>双烯雌酚</td>\n    <td>5毫克3次/天</td>\n   </tr>\n   <tr>\n    <td rowspan=\"5\">肠内注射或皮下注射</td>\n    <td>苯甲酸雌二醇</td>\n    <td>每周5毫克2-3次</td>\n   </tr>\n   <tr>\n    <td>二丙酸雌二醇</td>\n    <td>每周5毫克3次</td>\n   </tr>\n   <tr>\n    <td>雌二醇戊酸酯</td>\n    <td>30毫克1次/2周</td>\n   </tr>\n   <tr>\n    <td>聚雌二醇磷酸酯</td>\n    <td>40–80毫克1次/4周</td>\n   </tr>\n   <tr>\n    <td>雌酮</td>\n    <td>5毫克≥3次/周</td>\n   </tr>\n   <tr>\n    <td colspan=\"3\">注：（1）仅适用于绝经至少5年的女性。（2）剂量不一定相等。</td>\n   </tr>\n   <tr>\n    <td colspan=\"3\">雌激素用于前列腺癌的剂量</td>\n   </tr>\n   <tr>\n    <td>路径/形式</td>\n    <td>雌激素</td>\n    <td>剂量</td>\n   </tr>\n   <tr>\n    <td rowspan=\"11\">口服</td>\n    <td>雌二醇</td>\n    <td>1-2毫克3次/天</td>\n   </tr>\n   <tr>\n    <td>共轭雌激素</td>\n    <td>1.25–2.5毫克3次/天</td>\n   </tr>\n   <tr>\n    <td>炔雌醇</td>\n    <td>0.15–2毫克/天</td>\n   </tr>\n   <tr>\n    <td>炔雌醇磺酸盐</td>\n    <td>每周1-2毫克1次</td>\n   </tr>\n   <tr>\n    <td>己烯雌酚</td>\n    <td>1-3毫克/天</td>\n   </tr>\n   <tr>\n    <td>双烯雌酚</td>\n    <td>5毫克/天</td>\n   </tr>\n   <tr>\n    <td>己烷雌酚</td>\n    <td>5毫克/天</td>\n   </tr>\n   <tr>\n    <td>磷雌酚</td>\n    <td>每天120-480毫克1-3次</td>\n   </tr>\n   <tr>\n    <td>氯烯雌醚</td>\n    <td>12-24毫克/天</td>\n   </tr>\n   <tr>\n    <td>夸屈硅烷</td>\n    <td>900毫克/天</td>\n   </tr>\n   <tr>\n    <td>雌莫司汀磷酸盐</td>\n    <td>140-1400毫克/天</td>\n   </tr>\n   <tr>\n    <td>透皮贴剂</td>\n    <td>雌二醇</td>\n    <td>2–6x 100μg/天<p>阴囊：1x 100微克/天</p></td>\n   </tr>\n   <tr>\n    <td rowspan=\"6\">肠内注射或皮下注射</td>\n    <td>苯甲酸雌二醇酯</td>\n    <td>每周1.66毫克3次</td>\n   </tr>\n   <tr>\n    <td>二丙酸雌二醇酯</td>\n    <td>每周5毫克1次</td>\n   </tr>\n   <tr>\n    <td>雌二醇戊酸酯</td>\n    <td>10-40毫克1次/1-2周</td>\n   </tr>\n   <tr>\n    <td>十一酸雌二醇酯</td>\n    <td>100毫克1次/4周</td>\n   </tr>\n   <tr>\n    <td>聚乙二醇磷酸酯</td>\n    <td>单独使用：160–320毫克1次/4周<p>口服EE：40–80毫克1次/4周</p></td>\n   </tr>\n   <tr>\n    <td>雌酮</td>\n    <td>每周2-4毫克2-3次</td>\n   </tr>\n   <tr>\n    <td rowspan=\"2\">静脉注射</td>\n    <td>磷雌酚</td>\n    <td>每周300-1200毫克1-7次</td>\n   </tr>\n   <tr>\n    <td>雌莫司汀磷酸盐</td>\n    <td>240–450毫克/天</td>\n   </tr>\n   <tr>\n    <td colspan=\"3\">注意：剂量不一定相等。</td>\n   </tr>\n  </tbody>\n </table></p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994946826174979","title":"副作用","versionId":"52068869845600266","lemmaId":10120,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598331464,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>口服剂量超过1毫克/天时，DES的副作用发生率较高，包括恶心、呕吐、腹部不适、头痛和腹胀，发生率为15%至50%。<sup><a href=\"#quote_24\" class=\"kx_ref\">[24]</a></sup> </p><p>在以DES作为一种男性前列腺癌高剂量雌激素疗法形式的研究中，DES与心血管发病率和死亡率有很大关系。<sup><a href=\"#quote_25\" class=\"kx_ref\">[25]</a></sup> 风险取决于剂量。<sup><a href=\"#quote_25\" class=\"kx_ref\">[25]</a></sup> 5毫克/天的DES剂量与36%的非癌症（主要是心血管）死亡增长相关。<sup><a href=\"#quote_25\" class=\"kx_ref\">[25]</a></sup> 此外，静脉血栓栓塞的发生率高达15%。<sup><a href=\"#quote_25\" class=\"kx_ref\">[25]</a></sup> 3毫克/天的DES剂量与9.6%至17%的血栓栓塞发生率相关，心血管并发症发生率为33.3%。<sup><a href=\"#quote_25\" class=\"kx_ref\">[25]</a></sup> 1毫克/天的低剂量DES与14.8%的心血管事件导致的死亡率相关（与之相比，单纯睾丸切除术的死亡率为8.3%）。<sup><a href=\"#quote_25\" class=\"kx_ref\">[25]</a></sup> </p><p>在接受前列腺癌治疗的男性中，发现DES会产生41%至77%的男性乳房发育症（乳房发育）。<sup><a href=\"#quote_26\" class=\"kx_ref\">[26]</a></sup> </p><p><h3>长期影响</h3></p><p>DES与多种长期不良反应有关，如在怀孕期间接受DES治疗的妇女和/或其后代患阴道透明细胞腺癌、阴道腺病、T形子宫、子宫肌瘤、宫颈机能不全、乳腺癌、不孕症、性腺机能减退、间体缺陷、抑郁症等的风险增加。<sup><a href=\"#quote_27\" class=\"kx_ref\">[27]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994946842952194","title":"用药过量","versionId":"52068869845600267","lemmaId":10120,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598331464,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>在过去的临床研究中，高达1500毫克/天的DES被评估为极高剂量。<sup><a href=\"#quote_28\" class=\"kx_ref\">[28]</a></sup><sup><a href=\"#quote_28\" class=\"kx_ref\">[28]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994946842952195","title":"药理学","versionId":"52068869845600268","lemmaId":10120,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598331464,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><h3>药效学</h3></p><p><strong>雌激素活性</strong></p><p>DES是一种雌激素；具体而言，它是两种雌激素受体（ERs）的高效全激动剂。<sup><a href=\"#quote_29\" class=\"kx_ref\">[29]</a></sup><sup><a href=\"#quote_30\" class=\"kx_ref\">[30]</a></sup> DES对雌激素受体α和雌激素受体β的亲和力分别约为468%和295%。<sup><a href=\"#quote_31\" class=\"kx_ref\">[31]</a></sup> 然而，据报道，DES与雌激素受体α和雌激素受体β的EC50值分别为0.18 nM和0.06 nM，这表明，尽管DES与两种受体具有结合亲和力，但对于雌激素受体β的激活比雌激素受体α高出数倍。<sup><a href=\"#quote_32\" class=\"kx_ref\">[32]</a></sup> </p><p>就全身雌激素效力而言，1毫克/天DES的剂量大约相当于50克/天炔雌醇的剂量。<sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup> 与炔雌醇相似，DES对肝脏蛋白质合成有显著且不成比例的强烈作用。<sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup> 尽管其系统雌激素效力约是与微粉化雌二醇具有相似效力的雌酮酯（硫酸哌嗪雌酮）的3.8倍，但DES的肝脏雌激素效力是雌酮酯的28.4倍（或具有同等系统雌激素效力的剂量的约7.5倍强效力）。<sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup> </p><p>DES在治疗男性前列腺癌中至少有三种作用机制。<sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup> 由于其抗促性腺激素的作用，它能够抑制性腺雄激素的产生，从而抑制循环雄激素水平；它可以刺激肝脏性激素结合球蛋白（SHBG）的产生，从而增加SHBG循环水平，降低循环中睾酮和二氢睾酮的游离分数；并且它可能对睾丸和前列腺具有直接的细胞毒性作用。<sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup> 此外，高剂量的DES会减少脱氧核糖核酸的合成。<sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup> </p><p>DES是一种长效雌激素，细胞核驻留时间约为24小时。<sup><a href=\"#quote_35\" class=\"kx_ref\">[35]</a></sup> </p><p>\n <table class=\"wikitable\">\n  <tbody>\n   <tr>\n    <td colspan=\"18\">雌激素的相对口服功效</td>\n   </tr>\n   <tr>\n    <td>雌激素</td>\n    <td colspan=\"2\">类型</td>\n    <td colspan=\"2\">HF</td>\n    <td>VE</td>\n    <td>UCa</td>\n    <td colspan=\"2\">FSH</td>\n    <td colspan=\"2\">LH</td>\n    <td>HDL-C</td>\n    <td>SHBG</td>\n    <td colspan=\"2\">CBG</td>\n    <td colspan=\"2\">AGT</td>\n    <td>Liver</td>\n   </tr>\n   <tr>\n    <td>雌二醇</td>\n    <td colspan=\"2\">生物识别</td>\n    <td colspan=\"2\">1</td>\n    <td>1</td>\n    <td>1</td>\n    <td colspan=\"2\">1</td>\n    <td colspan=\"2\">1</td>\n    <td>1</td>\n    <td>1</td>\n    <td colspan=\"2\">1</td>\n    <td colspan=\"2\">1</td>\n    <td>1</td>\n   </tr>\n   <tr>\n    <td>雌酮</td>\n    <td colspan=\"2\">生物识别</td>\n    <td colspan=\"2\">？</td>\n    <td>？</td>\n    <td>？</td>\n    <td colspan=\"2\">0.3</td>\n    <td colspan=\"2\">0.3</td>\n    <td>？</td>\n    <td>？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td>？</td>\n   </tr>\n   <tr>\n    <td>雌三醇</td>\n    <td colspan=\"2\">生物识别</td>\n    <td colspan=\"2\">0.3</td>\n    <td>0.3</td>\n    <td>0.1</td>\n    <td colspan=\"2\">0.3</td>\n    <td colspan=\"2\">0.3</td>\n    <td>0.2</td>\n    <td>？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td>0.67</td>\n   </tr>\n   <tr>\n    <td>雌酮硫酸盐</td>\n    <td colspan=\"2\">生物识别</td>\n    <td colspan=\"2\">？</td>\n    <td>0.9</td>\n    <td>0.9</td>\n    <td colspan=\"2\">0.9</td>\n    <td colspan=\"2\">0.9</td>\n    <td>0.5</td>\n    <td>0.9</td>\n    <td colspan=\"2\">0.7</td>\n    <td colspan=\"2\">1.5</td>\n    <td>0.56–1.7</td>\n   </tr>\n   <tr>\n    <td>共轭雌激素</td>\n    <td colspan=\"2\">天然的</td>\n    <td colspan=\"2\">1.2</td>\n    <td>1.5</td>\n    <td>2</td>\n    <td colspan=\"2\">1.1</td>\n    <td colspan=\"2\">1</td>\n    <td>1.5</td>\n    <td>3</td>\n    <td colspan=\"2\">1.5</td>\n    <td colspan=\"2\">5</td>\n    <td>1.3–4.5</td>\n   </tr>\n   <tr>\n    <td>硫酸木贼素</td>\n    <td colspan=\"2\">天然的</td>\n    <td colspan=\"2\">？</td>\n    <td>？</td>\n    <td>1</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td>6</td>\n    <td>7.5</td>\n    <td colspan=\"2\">6</td>\n    <td colspan=\"2\">7.5</td>\n    <td>？</td>\n   </tr>\n   <tr>\n    <td>炔雌醇</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">120</td>\n    <td>150</td>\n    <td>400</td>\n    <td colspan=\"2\">120</td>\n    <td colspan=\"2\">100</td>\n    <td>400</td>\n    <td>500</td>\n    <td colspan=\"2\">600</td>\n    <td colspan=\"2\">350</td>\n    <td>2.9–5.0</td>\n   </tr>\n   <tr>\n    <td>己烯雌酚</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">？</td>\n    <td>？</td>\n    <td>？</td>\n    <td colspan=\"2\">3.4</td>\n    <td colspan=\"2\">？</td>\n    <td>？</td>\n    <td>25.6</td>\n    <td colspan=\"2\">24.5</td>\n    <td colspan=\"2\">19.5</td>\n    <td>5.7–7.5</td>\n   </tr>\n   <tr>\n    <td colspan=\"18\">注：数值为比值，雌二醇为标准值（即1.0）。缩写：HF =热潮红的临床缓解。VE =阴道上皮细胞增殖增加。UCa =尿钙的降低。VE=卵泡刺激素水平的抑制。LH=黄体生成素水平的抑制。HDL-C、SHBG、CBG和AGT =这些肝脏蛋白质的血清水平增加。Liver=肝脏雌激素效应与全身/全身雌激素效应的比率（特别是热潮红缓解和促性腺激素抑制）。类型：生物识别=与在人类身上发现的相同。天然的=天然存在，但与人类中发现的不同（例如，其他物种的雌激素）。合成的=人造的，不会在动物或环境中自然发生。</td>\n   </tr>\n   <tr>\n    <td colspan=\"18\">雌激素的口服功效</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\" rowspan=\"2\">雌激素</td>\n    <td colspan=\"2\" rowspan=\"2\">类型</td>\n    <td colspan=\"2\" rowspan=\"2\">分类</td>\n    <td colspan=\"2\">ETD</td>\n    <td colspan=\"2\">EPD</td>\n    <td colspan=\"2\">EPD</td>\n    <td colspan=\"2\">MSD</td>\n    <td colspan=\"2\">MSD</td>\n    <td colspan=\"2\">TSD</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">（毫克/14天）</td>\n    <td colspan=\"2\">（毫克/14天）</td>\n    <td colspan=\"2\">（毫克/天）</td>\n    <td colspan=\"2\">（毫克/14天）</td>\n    <td colspan=\"2\">（毫克/天）</td>\n    <td colspan=\"2\">（毫克/天）</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">雌二醇（微粉化）</td>\n    <td colspan=\"2\">生物识别</td>\n    <td colspan=\"2\">类固醇</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">60–80</td>\n    <td colspan=\"2\">4.3</td>\n    <td colspan=\"2\">14–28岁</td>\n    <td colspan=\"2\">1.0–2.0</td>\n    <td colspan=\"2\">&gt; 8</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">雌二醇戊酸酯</td>\n    <td colspan=\"2\">生物识别</td>\n    <td colspan=\"2\">类固醇</td>\n    <td colspan=\"2\">6–10</td>\n    <td colspan=\"2\">60–80</td>\n    <td colspan=\"2\">4.3</td>\n    <td colspan=\"2\">14–28岁</td>\n    <td colspan=\"2\">1.0–2.0</td>\n    <td colspan=\"2\">&gt; 8</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">雌三醇</td>\n    <td colspan=\"2\">生物识别</td>\n    <td colspan=\"2\">类固醇</td>\n    <td colspan=\"2\">20<sup>a</sup> </td>\n    <td colspan=\"2\">120–150 ‑</td>\n    <td colspan=\"2\">10.0–10.7 <sup>b</sup> </td>\n    <td colspan=\"2\">28–84</td>\n    <td colspan=\"2\">1.0–6.0</td>\n    <td colspan=\"2\">？</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">雌三醇琥珀酸酯</td>\n    <td colspan=\"2\">生物识别</td>\n    <td colspan=\"2\">类固醇</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">140–150 <sup>b</sup> </td>\n    <td colspan=\"2\">10.0–10.7 <sup>b</sup> </td>\n    <td colspan=\"2\">28–84</td>\n    <td colspan=\"2\">2.0–6.0</td>\n    <td colspan=\"2\">？</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">共轭雌激素</td>\n    <td colspan=\"2\">天然的</td>\n    <td colspan=\"2\">类固醇</td>\n    <td colspan=\"2\">5–12</td>\n    <td colspan=\"2\">60–80</td>\n    <td colspan=\"2\">4.3</td>\n    <td colspan=\"2\">8.4–17.5</td>\n    <td colspan=\"2\">0.625–1.25</td>\n    <td colspan=\"2\">7.5</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">炔雌醇</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">类固醇</td>\n    <td colspan=\"2\">0.2</td>\n    <td colspan=\"2\">1.0–2.0</td>\n    <td colspan=\"2\">0.071–0.11</td>\n    <td colspan=\"2\">0.28</td>\n    <td colspan=\"2\">0.02</td>\n    <td colspan=\"2\">0.1</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">炔雌醇甲醚</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">类固醇</td>\n    <td colspan=\"2\">0.3</td>\n    <td colspan=\"2\">1.5–3.0</td>\n    <td colspan=\"2\">0.11–0.13</td>\n    <td colspan=\"2\">0.3–0.5</td>\n    <td colspan=\"2\">0.025</td>\n    <td colspan=\"2\">？</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">喹雌酮</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">类固醇</td>\n    <td colspan=\"2\">0.3</td>\n    <td colspan=\"2\">2.0–4.0</td>\n    <td colspan=\"2\">0.14–0.29</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">0.025–0.05</td>\n    <td colspan=\"2\">？</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">甲基雌二醇</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">类固醇</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">2</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">己烯雌酚</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">非甾体化合物</td>\n    <td colspan=\"2\">2.5</td>\n    <td colspan=\"2\">20–30</td>\n    <td colspan=\"2\">1.4–2.1</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">0.5–2.0</td>\n    <td colspan=\"2\">3</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">二丙酸己烯雌酚</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">非甾体化合物</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">15–30</td>\n    <td colspan=\"2\">1.1–1.4</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">双烯雌酚</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">非甾体化合物</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">30</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">0.5–4.0</td>\n    <td colspan=\"2\">？</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">双烯雌酚二乙酸酯</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">非甾体化合物</td>\n    <td colspan=\"2\">3–5</td>\n    <td colspan=\"2\">30–60</td>\n    <td colspan=\"2\">2.9–4.3</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">己烷雌酚</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">非甾体化合物</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">70–110</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">己烷雌酚二乙酸酯</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">非甾体化合物</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">45</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">多口服</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">非甾体化合物</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">&gt; 100</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n   </tr>\n   <tr>\n    <td colspan=\"2\">甲基雌激素</td>\n    <td colspan=\"2\">合成的</td>\n    <td colspan=\"2\">非甾体化合物</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">400</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n    <td colspan=\"2\">？</td>\n   </tr>\n   <tr>\n    <td colspan=\"18\">注：EE的OID值为0.1毫克/天。脚注：a =变化很大，通常更高。b =分剂量，每天3次；不规则和不典型的扩散。</td>\n   </tr>\n   <tr>\n    <td colspan=\"18\">非甾体雌激素的胃肠外效力和持续时间</td>\n   </tr>\n   <tr>\n    <td colspan=\"5\">雌激素</td>\n    <td colspan=\"4\">ETD（14天）</td>\n    <td colspan=\"9\">期间</td>\n   </tr>\n   <tr>\n    <td colspan=\"5\">己烯雌酚</td>\n    <td colspan=\"4\">20毫克</td>\n    <td colspan=\"4\">3毫克≈ 3天</td>\n    <td colspan=\"5\"></td>\n   </tr>\n   <tr>\n    <td colspan=\"5\">二丙酸己烯雌酚</td>\n    <td colspan=\"4\">12.5-15毫克</td>\n    <td colspan=\"4\">2.5毫克≈ 5天</td>\n    <td colspan=\"5\"></td>\n   </tr>\n   <tr>\n    <td colspan=\"5\">己烯雌酚二丙酸酯（晶体。悬浊液。）</td>\n    <td colspan=\"4\">5毫克</td>\n    <td colspan=\"4\">？mg = 21-28天</td>\n    <td colspan=\"5\"></td>\n   </tr>\n   <tr>\n    <td colspan=\"5\">双烯雌酚二乙酸酯（晶体。susp。）</td>\n    <td colspan=\"4\">50毫克</td>\n    <td colspan=\"4\">？</td>\n    <td colspan=\"5\"></td>\n   </tr>\n   <tr>\n    <td colspan=\"5\">二甲己烯雌酚</td>\n    <td colspan=\"4\">20-40毫克</td>\n    <td colspan=\"4\">？</td>\n    <td colspan=\"5\"></td>\n   </tr>\n   <tr>\n    <td colspan=\"5\">二丙酸己雌醇酯</td>\n    <td colspan=\"4\">25毫克</td>\n    <td colspan=\"4\">？</td>\n    <td colspan=\"5\"></td>\n   </tr>\n   <tr>\n    <td colspan=\"13\">注：均为通过注射油剂，除非另有说明。</td>\n    <td colspan=\"5\"></td>\n   </tr>\n  </tbody>\n </table></p><p><strong>抗促性腺激素效应</strong></p><p>由于其雌激素活性，DES具有抗促性腺激素作用。<sup><a href=\"#quote_36\" class=\"kx_ref\">[36]</a></sup><sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup><sup><a href=\"#quote_37\" class=\"kx_ref\">[37]</a></sup><sup><a href=\"#quote_38\" class=\"kx_ref\">[38]</a></sup> 也就是说，它对下丘脑-垂体-性腺轴（HPG轴）施加负反馈，抑制促性腺激素、黄体生成素和卵泡刺激素的分泌，并抑制性激素的产生以及性腺中生殖细胞的产生或成熟。<sup><a href=\"#quote_36\" class=\"kx_ref\">[36]</a></sup><sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup><sup><a href=\"#quote_37\" class=\"kx_ref\">[37]</a></sup><sup><a href=\"#quote_38\" class=\"kx_ref\">[38]</a></sup> 在1至2周内以3毫克/天及以上的剂量下，DES持续地将男性睾酮水平抑制在阉割范围内（&lt; 50纳克/分升）。<sup><a href=\"#quote_36\" class=\"kx_ref\">[36]</a></sup><sup><a href=\"#quote_38\" class=\"kx_ref\">[38]</a></sup> 相反，1毫克/天DES的剂量不能完全抑制男性睾酮水平进入阉割范围，而是通常使睾酮水平稳定在略高于阉割水平（&gt; 50纳克/分升）。<sup><a href=\"#quote_39\" class=\"kx_ref\">[39]</a></sup><sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup><sup><a href=\"#quote_37\" class=\"kx_ref\">[37]</a></sup> 然而，也有报道称，1毫克/天的DES可抑制约50%的睾酮水平，尽管个体间差异很大。<sup><a href=\"#quote_36\" class=\"kx_ref\">[36]</a></sup> 据说每日剂量少于1毫克的DES对睾酮水平没有影响。<sup><a href=\"#quote_36\" class=\"kx_ref\">[36]</a></sup> 然而，已发现向醋酸环丙孕酮中添加0.1毫克/天的“极低”剂量DES可产生协同抗促性腺激素的作用，并抑制男性睾酮水平进入阉割范围。<sup><a href=\"#quote_39\" class=\"kx_ref\">[39]</a></sup><sup><a href=\"#quote_40\" class=\"kx_ref\">[40]</a></sup><sup><a href=\"#quote_41\" class=\"kx_ref\">[41]</a></sup> </p><p><strong>其他作用</strong></p><p>除了雌激素受体之外，一项体外研究发现，DES还对多种其他类固醇激素受体具有活性，虽然这些活性相对较弱。<sup><a href=\"#quote_32\" class=\"kx_ref\">[32]</a></sup> 尽管研究发现雌激素受体α和雌激素受体β的半数致死浓度分别为0.18纳摩和0.06纳摩，但该药物在1微摩浓度下显示出明显的糖皮质激素活性，超过了0.1纳摩地塞米松的浓度，并且雄激素、孕酮和盐皮质激素受体具有明显的拮抗作用（分别为75%、85%和50%抑制阳性对照刺激，浓度均在1微摩）。<sup><a href=\"#quote_32\" class=\"kx_ref\">[32]</a></sup>研究人员表示，据他们所知，他们是第一个报道DES这种作用的人，并假设这些作用可能与DES的临床效应有关，例如前列腺癌（特别是使用了特别高剂量的DES）。然而，他们也指出，这些作用的重要性需要在药理学相关剂量的动物模型中进一步研究。<sup><a href=\"#quote_32\" class=\"kx_ref\">[32]</a></sup> </p><p>DES已被鉴定为三种同种类型雌激素相关受体（ERRs）：ERRα、ERRβ和ERRγ的拮抗剂。<sup><a href=\"#quote_42\" class=\"kx_ref\">[42]</a></sup> </p><p><h3>药代动力学</h3></p><p>口服DES吸收良好。<sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup> 口服剂量为1毫克/天时，最后一次剂量后20小时的血浆DES水平在0.9-1.9纳克/毫升（3.4-7.1纳摩尔/升）之间。<sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup> DES的分布半衰期为80分钟。<sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup> 它对SHBG或皮质类固醇结合球蛋白没有亲和力，因此在循环中不与这些蛋白质结合。<sup><a href=\"#quote_43\" class=\"kx_ref\">[43]</a></sup> DES的血浆蛋白结合率大于95%。<sup><a href=\"#quote_44\" class=\"kx_ref\">[44]</a></sup> DES芳环的羟基化和随后与乙基侧链的接合占DES代谢的80-90%，而氧化占剩余的10-20%，并且主要是结合反应。<sup><a href=\"#quote_44\" class=\"kx_ref\">[44]</a></sup><sup><a href=\"#quote_45\" class=\"kx_ref\">[45]</a></sup> DES的结合包括葡萄糖醛酸化，而氧化包括脱氢成（Z，Z）-二烯雌酚。<sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup><sup><a href=\"#quote_44\" class=\"kx_ref\">[44]</a></sup><sup><a href=\"#quote_45\" class=\"kx_ref\">[45]</a></sup> 还已知该药物会产生作为代谢物的丙氧基丙酸。<sup><a href=\"#quote_46\" class=\"kx_ref\">[46]</a></sup> DES产生短暂的醌类活性中间体，导致细胞和遗传损伤，这可能解释了DES对人类已知的致癌作用。<sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup> 然而，其他研究表明DES的毒性作用可能仅仅是由于ERs的过度激活。<sup><a href=\"#quote_47\" class=\"kx_ref\">[47]</a></sup> DES的消除半衰期为24小时。<sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup> DES的代谢物通过尿液和粪便排出体外。<sup><a href=\"#quote_44\" class=\"kx_ref\">[44]</a></sup><sup><a href=\"#quote_45\" class=\"kx_ref\">[45]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994946842952196","title":"化学","versionId":"51190979016828683","lemmaId":10120,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78012871,"name":"卤蛋","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1597808201,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"324\" img_width=\"265\" titlename=\"雌二醇和DES的化学结构。[1] 注意DES中存在两个羟基，它们之间的距离与雌二醇两个羟基之间的距离相似，当认为DES是被偶然发现的时候，这一点值得注意。[1][2][3]\" data-src=\"https://img03.sogoucdn.com/app/a/200698/sogou_science_1048\"> </p><p>DES属于二苯乙烯（4，4’-二羟基二苯乙烯）类化合物。<sup><a href=\"#quote_48\" class=\"kx_ref\">[48]</a></sup> 它是甾体雌激素雌二醇的非甾体开环类似物。<sup><a href=\"#quote_49\" class=\"kx_ref\">[49]</a></sup> DES源自天然化合物茴香脑，属于茴香和茴香籽的一种弱雌激素成分。<sup><a href=\"#quote_48\" class=\"kx_ref\">[48]</a></sup><sup><a href=\"#quote_50\" class=\"kx_ref\">[50]</a></sup><sup><a href=\"#quote_51\" class=\"kx_ref\">[51]</a></sup><sup><a href=\"#quote_52\" class=\"kx_ref\">[52]</a></sup> 茴香脑脱甲基形成对丙烯基苯酚，然后对丙烯基苯酚自发二聚成二乙醇和己烷雌酚，DES随后通过己烷雌酚的结构修饰合成。<sup><a href=\"#quote_48\" class=\"kx_ref\">[48]</a></sup><sup><a href=\"#quote_50\" class=\"kx_ref\">[50]</a></sup><sup><a href=\"#quote_51\" class=\"kx_ref\">[51]</a></sup><sup><a href=\"#quote_52\" class=\"kx_ref\">[52]</a></sup> 通过x射线晶体学已经确定DES的分子尺寸与雌二醇的分子尺寸几乎相同，特别是分子两端羟基之间的距离。<sup><a href=\"#quote_52\" class=\"kx_ref\">[52]</a></sup> </p>","pics":[{"originalUrl":"https://web.archive.org/web/20221029032313/https://img03.sogoucdn.com/app/a/200698/sogou_science_1048?w=265&h=324&titlename=%E9%9B%8C%E4%BA%8C%E9%86%87%E5%92%8CDES%E7%9A%84%E5%8C%96%E5%AD%A6%E7%BB%93%E6%9E%84%E3%80%82%5B1%5D%20%E6%B3%A8%E6%84%8FDES%E4%B8%AD%E5%AD%98%E5%9C%A8%E4%B8%A4%E4%B8%AA%E7%BE%9F%E5%9F%BA%EF%BC%8C%E5%AE%83%E4%BB%AC%E4%B9%8B%E9%97%B4%E7%9A%84%E8%B7%9D%E7%A6%BB%E4%B8%8E%E9%9B%8C%E4%BA%8C%E9%86%87%E4%B8%A4%E4%B8%AA%E7%BE%9F%E5%9F%BA%E4%B9%8B%E9%97%B4%E7%9A%84%E8%B7%9D%E7%A6%BB%E7%9B%B8%E4%BC%BC%EF%BC%8C%E5%BD%93%E8%AE%A4%E4%B8%BADES%E6%98%AF%E8%A2%AB%E5%81%B6%E7%84%B6%E5%8F%91%E7%8E%B0%E7%9A%84%E6%97%B6%E5%80%99%EF%BC%8C%E8%BF%99%E4%B8%80%E7%82%B9%E5%80%BC%E5%BE%97%E6%B3%A8%E6%84%8F%E3%80%82%5B1%5D%5B2%5D%5B3%5D","url":"https://web.archive.org/web/20221029032313/https://img03.sogoucdn.com/app/a/200698/sogou_science_1048","rw":265,"rh":324,"title":"雌二醇和DES的化学结构。[1] 注意DES中存在两个羟基，它们之间的距离与雌二醇两个羟基之间的距离相似，当认为DES是被偶然发现的时候，这一点值得注意。[1][2][3]","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"14994946859729414","title":"历史","versionId":"52068869845600269","lemmaId":10120,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598331464,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><h3>合成</h3></p><p>1938年初，利昂·戈尔堡首次合成了DES，后来他成为了牛津大学戴森·佩林斯实验室罗伯特·罗宾逊爵士的一名研究生。戈尔堡的研究是基于考陶德生物化学研究所的威尔弗里德·劳森的工作（由米德尔塞克斯医院医学院的爱德华·查尔斯·多德爵士领导，米德尔塞克斯医院医学院现在是伦敦大学学院的一部分）。其合成报告于1938年2月5日发表在《自然》杂志上。<sup><a href=\"#quote_53\" class=\"kx_ref\">[53]</a></sup><sup><a href=\"#quote_54\" class=\"kx_ref\">[54]</a></sup><sup><a href=\"#quote_55\" class=\"kx_ref\">[55]</a></sup> </p><p>DES研究由英国医学研究委员会（MRC）资助，该委员会制定了一项禁止使用公共资金对发现的药物申请专利的政策。由于没有专利，DES由全球200多家制药和化学公司生产。</p><p><h3>临床应用</h3></p><p>1941年9月19日，美国食品和药物管理局（FDA）批准了DES（在片剂中最多5毫克）的四种适应症：淋病性阴道炎、萎缩性阴道炎、更年期症状和产后泌乳抑制，以防止乳房充血。<sup><a href=\"#quote_55\" class=\"kx_ref\">[55]</a></sup> 抗生素青霉素上市后，淋病性阴道炎的适应症就取消了。从一开始，这种药物就备受争议。<sup><a href=\"#quote_56\" class=\"kx_ref\">[56]</a></sup><sup><a href=\"#quote_57\" class=\"kx_ref\">[57]</a></sup> </p><p>1941年，芝加哥大学的查尔斯·哈金斯和克拉伦斯·霍奇斯发现DES是第一种治疗转移性前列腺癌的有效药物。<sup><a href=\"#quote_58\" class=\"kx_ref\">[58]</a></sup><sup><a href=\"#quote_59\" class=\"kx_ref\">[59]</a></sup> </p><p>睾丸切除术或DES或两者兼顾40多年来症状性晚期前列腺癌的标准初始治疗方法，直到GnRH激动剂亮丙瑞林被发现具有与DES相似的疗效且无雌激素效应，并于1985年获得批准。<sup><a href=\"#quote_60\" class=\"kx_ref\">[60]</a></sup> </p><p>从20世纪40年代到80年代末，DES被美国食品和药物管理局批准作为雌激素缺乏状态（如卵巢发育不良、卵巢早衰和卵巢切除术后）的雌激素替代疗法。</p><p>20世纪40年代，在有流产史的妇女中，DES作为未被临床认可的药物来预防不良妊娠结局。1947年7月1日，美国食品和药物管理局批准将DES应用于这种适应症。首次批准授予百时美施贵宝公司，允许在怀孕期间使用25毫克（后来是100毫克）的DES片剂。同年晚些时候，其他制药公司也获得了批准。<sup><a href=\"#quote_61\" class=\"kx_ref\">[61]</a></sup> 推荐的方案从妊娠第七周和第八周（从末次月经的第一天开始）每天5毫克开始，到第十四周每隔一周增加5毫克，然后从妊娠第十五周的每天25毫克增加到妊娠第三十五周的每天125毫克。<sup><a href=\"#quote_62\" class=\"kx_ref\">[62]</a></sup> DES最初被认为对孕妇和发育中的婴儿都是有效和安全的。它被大力推广，并成为常规处方。销售额在1953年达到顶峰。</p><p>20世纪50年代早期，芝加哥大学的一项双盲临床试验评估了妇女是否给DES药的妊娠结果。<sup><a href=\"#quote_63\" class=\"kx_ref\">[63]</a></sup> 这项研究表明怀孕期间服用DES没有好处；接受DES治疗的妇女的不良妊娠结果没有减少。到了20世纪60年代末，七本主要的产科教科书中有六本称DES在预防流产方面无效。<sup><a href=\"#quote_61\" class=\"kx_ref\">[61]</a></sup><sup><a href=\"#quote_64\" class=\"kx_ref\">[64]</a></sup> </p><p>尽管没有证据支持使用DES可以预防不良妊娠结局，但DES在20世纪60年代一直被用于孕妇。1971年，发表在《新英格兰医学杂志》上的一份报告显示，在子宫内接触这种药物的女孩和年轻女性中，DES与阴道透明细胞腺癌之间可能存在关联。同年晚些时候，美国食品和药物管理局向所有美国医生发送了一份美国食品和药物管理局药品公告，建议不要在孕妇中使用DES。美国食品和药物管理局还取消了预防流产作为DES使用的适应症，并增加了妊娠作为DES使用的禁忌症。<sup><a href=\"#quote_65\" class=\"kx_ref\">[65]</a></sup> 1975年2月5日，美国食品和药物管理局下令从1975年2月18日起撤回25毫克和100毫克的DES片剂。<sup><a href=\"#quote_66\" class=\"kx_ref\">[66]</a></sup> 1940年至1971年期间，妊娠期或子宫内接触DES的人数不详，但在美国可能高达200万。DES也被应用于其他国家，最显著的是法国、荷兰和英国。</p><p>从20世纪50年代到70年代初，DES被用于即将开始青春期的青春期前女孩，通过关闭骨骼中的生长板来使她们停止生长。尽管这种激素与癌症有明显的联系，但医生们仍继续推荐将这种激素用于“过度长高”。<sup><a href=\"#quote_67\" class=\"kx_ref\">[67]</a></sup> </p><p>1960年，在绝经后妇女晚期乳腺癌的治疗中，DES被认为比雄激素更有效。<sup><a href=\"#quote_68\" class=\"kx_ref\">[68]</a></sup> DES是绝经后妇女晚期乳腺癌的激素治疗选择，直到1977年，美国食品和药物管理局批准了三苯氧胺（他莫昔芬），这是一种选择性雌激素受体调节剂，其疗效与DES相似，但副作用较少。<sup><a href=\"#quote_69\" class=\"kx_ref\">[69]</a></sup> </p><p>20世纪70年代和80年代医学文献的几个来源表明，DES用于治疗变性人。<sup><a href=\"#quote_70\" class=\"kx_ref\">[70]</a></sup><sup><a href=\"#quote_71\" class=\"kx_ref\">[71]</a></sup><sup><a href=\"#quote_72\" class=\"kx_ref\">[72]</a></sup> </p><p>1973年，为了将未获得临床许可使用的DES作为如强奸等紧急情况后的性交后避孕方法（在1971年JAMA（美国医学协会）发表了一项有影响力的研究后，这种方法在许多大学卫生服务机构中逐渐普遍），美国食品和药物管理局向所有美国医生和药剂师发送了一份药物公报，称美国食品和药物管理局已在紧急条件下批准使用DES进行性交后避孕。<sup><a href=\"#quote_73\" class=\"kx_ref\">[73]</a></sup> </p><p>1975年，美国食品和药物管理局表示，他们实际上并未批准（也从未批准）任何制造商将DES作为性交后避孕药上市，但如果制造商按照美国食品和药物管理局在1975年最终公布的规定来提供患者标签和特殊包装，它将被批准用于强奸或乱伦等紧急情况适应症。<sup><a href=\"#quote_74\" class=\"kx_ref\">[74]</a></sup> 为了阻止未获得临床许可使用的DES作为性交后避孕药，美国食品和药物管理局于1975年从市场上撤下了DES 25毫克片剂，并下令将仍被批准用于其他适应症的较低剂量（5毫克及以下）的DES适应症改为“该药品不可用作性交后避孕药”，并在医生处方信息包装插页的第一行以及容器和纸箱标签的显著位置用大写印刷体书写。<sup><a href=\"#quote_66\" class=\"kx_ref\">[66]</a></sup><sup><a href=\"#quote_75\" class=\"kx_ref\">[75]</a></sup> 在20世纪80年代，未获得临床许可的Yuzpe疗法联合某些常规口服避孕药的使用，取代了DES作为性交后避孕药的未获得临床许可使用。<sup><a href=\"#quote_76\" class=\"kx_ref\">[76]</a></sup> </p><p>1978年，美国食品和药物管理局取消了产后哺乳抑制，以防止因为他们批准DES和其他雌激素的适应症而导致的乳房充血。<sup><a href=\"#quote_77\" class=\"kx_ref\">[77]</a></sup> 在20世纪90年代，DES的唯一批准适应症是晚期前列腺癌的治疗和绝经后妇女晚期乳腺癌的治疗。最后一家美国DES制造商礼来公司于1997年停止该药的生产和销售。</p><p><h3>诉讼</h3></p><p>20世纪70年代，围绕发现DES的长期影响的负面宣传在美国引发了针对其制造商的巨大诉讼浪潮。最终，加州最高法院在1980年做出了一项里程碑式的判决，辛德尔诉雅培实验室案，在该判决中，最高法院对所有DES制造商施加了一项可反驳的市场份额责任推定，其份额与特定原告母亲使用该药时其各自占有的市场份额成比例。</p><p>53名患有乳腺癌的女性向波士顿联邦法院提起诉讼，她们称自己的乳腺癌是母亲在怀孕期间服用DES的结果。他们的案子在道伯特听证会上幸存了下来。2013年，发起乳腺癌/DES链接诉讼的Fecho姐妹在审判的第二天同意支付一笔未披露的和解金额。其余的诉讼当事人已经得到了各种各样的和解。<sup><a href=\"#quote_78\" class=\"kx_ref\">[78]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994946859729415","title":"社会和文化","versionId":"52068869845600270","lemmaId":10120,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598331464,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>艾伦·图灵（Alan Turing），开创性的密码学家，计算科学和可编程计算机的创始人，他也提出了生物形态发生的实际理论模型，在死于模棱两可情况的前不久，他被迫服用药物导致化学阉割，作为对同性恋行为的惩罚性“治疗”。<sup><a href=\"#quote_79\" class=\"kx_ref\">[79]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994946859729416","title":"兽医用途","versionId":"52068869845600271","lemmaId":10120,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598331464,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><h3>犬失禁</h3></p><p>DES在治疗因括约肌控制不良引起的雌犬失禁方面非常成功。它仍然可以从药房买到，并且在低剂量（1毫克）下，不具有像对人类那样大的致癌特性。<sup><a href=\"#quote_80\" class=\"kx_ref\">[80]</a></sup> 通常每天给药一次，持续7-10天，然后根据需要每周给药一次。</p><p><h3>牲畜生长促进</h3></p><p>DES的最大用途是在畜牧业，用于改善牛肉和家禽的饲料转化率。在20世纪60年代，DES被用作牛肉和家禽行业的生长激素。后来在1971年，发现它会导致癌症，但直到1979年才被逐步淘汰。<sup><a href=\"#quote_81\" class=\"kx_ref\">[81]</a></sup><sup><a href=\"#quote_82\" class=\"kx_ref\">[82]</a></sup> 当发现DES对人类有害时，它被转移到兽医上使用。</p>","pics":null,"card":null,"references":[],"versionCount":0}],"references":[{"id":1,"type":"book","title":"Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 396–. ISBN 978-1-4757-2085-3.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":2,"type":"book","title":"Veurink M, Koster M, Berg LT (June 2005). \"The history of DES, lessons to be learned\". Pharm World Sci. 27 (3): 139–43. doi:10.1007/s11096-005-3663-z. PMID 16096877.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":3,"type":"book","title":"\"DES Update: For Consumers\". United States Department of Health and Human Services: Centers for Disease Control and Prevention. Retrieved 2011-06-30.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":4,"type":"book","title":"\"DES: Questions and Answers\". FactSheet. National Cancer Institute. Retrieved 2011-06-30.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":5,"type":"book","title":"Arnold, Amanda (January 5, 2017). \"The Devastating Effects of a 1940s 'Wonder Pill' Haunt Women Generations Later\". Broadly.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":6,"type":"book","title":"Coelingh Bennink HJ (April 2004). \"Are all estrogens the same?\". Maturitas. 47 (4): 269–75. doi:10.1016/j.maturitas.2003.11.009. PMID 15063479.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":7,"type":"book","title":"Noller KL, Fish CR (July 1974). \"Diethylstilbestrol usage: Its interesting past, important present, and questionable future\". Med. Clin. North Am. 58 (4): 793–810. doi:10.1016/S0025-7125(16)32122-8. PMID 4276416.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":8,"type":"book","title":"Thompson IM (2001). \"Flare Associated with LHRH-Agonist Therapy\". Rev Urol. 3 Suppl 3: S10–4. PMC 1476081. PMID 16986003.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":9,"type":"book","title":"Scaletscky R, Smith JA (April 1993). \"Disease flare with gonadotrophin-releasing hormone (GnRH) analogues. How serious is it?\". Drug Saf. 8 (4): 265–70. doi:10.2165/00002018-199308040-00001. PMID 8481213.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":10,"type":"book","title":"Kreis W, Ahmann FR, Jordan VC, de Haan H, Scott M (October 1988). \"Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation\". Br J Urol. 62 (4): 352–4. doi:10.1111/j.1464-410X.1988.tb04364.x. PMID 2973364.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":11,"type":"book","title":"Stein BS, Smith JA (April 1985). \"DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate\". Urology. 25 (4): 350–3. doi:10.1016/0090-4295(85)90484-4. PMID 3920802.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":12,"type":"book","title":"Fernandez del Moral P, Litjens TT, Weil EH, Debruyne FM (August 1988). \"Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?\". Urology. 32 (2): 137–40. doi:10.1016/0090-4295(88)90316-0. PMID 2969641.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":13,"type":"book","title":"Bruchovsky N, Goldenberg SL, Akakura K, Rennie PS (September 1993). \"Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol\". Cancer. 72 (5): 1685–91. doi:10.1002/1097-0142(19930901)72:5<1685::AID-CNCR2820720532>3.0.CO;2-3. PMID 7688656.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":14,"type":"book","title":"Kotake T, Usami M, Akaza H, Koiso K, Homma Y, Kawabe K, Aso Y, Orikasa S, Shimazaki J, Isaka S, Yoshida O, Hirao Y, Okajima E, Naito S, Kumazawa J, Kanetake H, Saito Y, Ohi Y, Ohashi Y (November 1999). \"Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group\". Jpn. J. Clin. Oncol. 29 (11): 562–70. doi:10.1093/jjco/29.11.562. PMID 10678560.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":15,"type":"book","title":"Reis LO, Zani EL, García-Perdomo HA (June 2018). \"Estrogen therapy in patients with prostate cancer: a contemporary systematic review\". Int Urol Nephrol. 50 (6): 993–1003. doi:10.1007/s11255-018-1854-5. PMID 29600433.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":16,"type":"book","title":"Bosset PO, Albiges L, Seisen T, de la Motte Rouge T, Phé V, Bitker MO, Rouprêt M (December 2012). \"Current role of diethylstilbestrol in the management of advanced prostate cancer\". BJU Int. 110 (11 Pt C): E826–9. doi:10.1111/j.1464-410X.2012.11206.x. PMID 22578092.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":17,"type":"book","title":"Scherr DS, Pitts WR (November 2003). \"The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer\". J. Urol. 170 (5): 1703–8. doi:10.1097/01.ju.0000077558.48257.3d. PMID 14532759.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":18,"type":"book","title":"Oh WK (September 2002). \"The evolving role of estrogen therapy in prostate cancer\". Clin Prostate Cancer. 1 (2): 81–9. PMID 15046698.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":19,"type":"book","title":"Malkowicz SB (August 2001). \"The role of diethylstilbestrol in the treatment of prostate cancer\". Urology. 58 (2 Suppl 1): 108–13. PMID 11502463.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":20,"type":"book","title":"Cox RL, Crawford ED (December 1995). \"Estrogens in the treatment of prostate cancer\". J. Urol. 154 (6): 1991–8. PMID 7500443.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":21,"type":"book","title":"Lycette JL, Bland LB, Garzotto M, Beer TM (December 2006). \"Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?\". Clin Genitourin Cancer. 5 (3): 198–205. doi:10.3816/CGC.2006.n.037. PMID 17239273.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":22,"type":"book","title":"Marselos M, Tomatis L (1992). \"Diethylstilboestrol: I, Pharmacology, Toxicology and carcinogenicity in humans\". Eur. J. Cancer. 28A (6–7): 1182–9. PMID 1627392.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":23,"type":"book","title":"Ellis, MJ; Dehdahti, F; Kommareddy, A; Jamalabadi-Majidi, S; Crowder, R; Jeffe, DB; Gao, F; Fleming, G; Silverman, P; Dickler, M; Carey, L; Marcom, PK (2014). \"A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer\". Cancer Research. 69 (2 Supplement): 16. doi:10.1158/0008-5472.SABCS-16. ISSN 0008-5472.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":24,"type":"book","title":"Swyer GI (April 1959). \"The oestrogens\". Br Med J. 1 (5128): 1029–31. doi:10.1136/bmj.1.5128.1029. PMC 1993181. PMID 13638626. [Diethylstilbestrol] suffers from the serious drawback that in doses above 1 mg. a day it is likely to produce nausea, vomiting, abdominal discomfort, headache, and bloating in a proportion of patients varyingly estimated from 15 to 50%.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":25,"type":"book","title":"Phillips I, Shah SI, Duong T, Abel P, Langley RE (2014). \"Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer\". Oncol Hematol Rev. 10 (1): 42–47. PMC 4052190. PMID 24932461.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":26,"type":"book","title":"Di Lorenzo G, Autorino R, Perdonà S, De Placido S (December 2005). \"Management of gynaecomastia in patients with prostate cancer: a systematic review\". Lancet Oncol. 6 (12): 972–9. doi:10.1016/S1470-2045(05)70464-2. PMID 16321765.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":27,"type":"book","title":"Bamigboye AA, Morris J (2003). \"Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes\". Cochrane Database Syst Rev (3): CD004353. doi:10.1002/14651858.CD004353. PMID 12918007.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":28,"type":"book","title":"Coelingh Bennink HJ, Verhoeven C, Dutman AE, Thijssen J (January 2017). \"The use of high-dose estrogens for the treatment of breast cancer\". Maturitas. 95: 11–23. doi:10.1016/j.maturitas.2016.10.010. PMID 27889048.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":29,"type":"book","title":"Jordan VC (2013). Estrogen Action, Selective Estrogen Receptor Modulators, and Women's Health: Progress and Promise. World Scientific. pp. 143–. ISBN 978-1-84816-958-6.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":30,"type":"book","title":"Seiler JP, Autrup JL, Autrup H (6 December 2012). Diversification in Toxicology — Man and Environment: Proceedings of the 1997 EUROTOX Congress Meeting Held in Århus, Denmark, June 25–28, 1997. Springer Science & Business Media. pp. 23–. ISBN 978-3-642-46856-8.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":31,"type":"book","title":"Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA (March 1997). \"Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta\". Endocrinology. 138 (3): 863–70. doi:10.1210/endo.138.3.4979. PMID 9048584.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":32,"type":"book","title":"Coss CC, Jones A, Parke DN, Narayanan R, Barrett CM, Kearbey JD, Veverka KA, Miller DD, Morton RA, Steiner MS, Dalton JT (March 2012). \"Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer\". Endocrinology. 153 (3): 1070–81. doi:10.1210/en.2011-1608. PMID 22294742.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":33,"type":"book","title":"Bruce Chabner; Dan Louis Longo (1996). Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott-Raven Publishers. p. 186. ISBN 978-0-397-51418-2. Piperazine estrone sulfate and micronized estradiol were equipotent with respect to increases in SHBG, whereas [...] DES was 28.4-fold more potent [...]. With respect to decreased FSH, [...] DES was 3.8-fold, and ethinyl estradiol was 80 to 200-fold more potent than was piperazine estrone sulfate. The dose equivalents for ethinyl estradiol (50 µg) and DES (1 mg) reflect these relative potencies.220 [...] DES, a potent synthetic estrogen (Fig. 6-12), is absorbed well after an oral dosage. Patients given 1 mg of DES daily had plasma concentrations at 20 hours ranging from 0.9 to 1.9 ng per mL. The initial half-life of DES is 80 minutes, with a secondary half-life of 24 hours.222 The principal pathways of metabolism are conversion to the glucuronide and oxidation. The oxidative pathways include aromatic hydroxylation of the ethyl side chains and dehydrogenation to (Z,Z)-dienestrol, producing transient quinone-like intermediates that react with cellular macromolecules and cause genetic damage in eukaryotic cells.223 Metabolic activation of DES may explain its well-established carcinogenic properties.224","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":34,"type":"book","title":"Kuhl H (August 2005). \"Pharmacology of estrogens and progestogens: influence of different routes of administration\" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":35,"type":"book","title":"Benno Runnebaum; Thomas Rabe (17 April 2013). Gynäkologische Endokrinologie und Fortpflanzungsmedizin: Band 1: Gynäkologische Endokrinologie. Springer-Verlag. pp. 88–. ISBN 978-3-662-07635-4.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":36,"type":"book","title":"Scott WW, Menon M, Walsh PC (April 1980). \"Hormonal Therapy of Prostatic Cancer\". Cancer. 45 Suppl 7: 1929–1936. doi:10.1002/cncr.1980.45.s7.1929. PMID 29603164.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":37,"type":"book","title":"Muhammad A. Salam (2003). Principles & Practice of Urology: A Comprehensive Text. Universal-Publishers. pp. 684–. ISBN 978-1-58112-412-5.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":38,"type":"book","title":"Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS (January 2006). \"Secondary hormonal therapy for advanced prostate cancer\". J. Urol. 175 (1): 27–34. doi:10.1016/S0022-5347(05)00034-0. PMID 16406864.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":39,"type":"book","title":"Turo R, Smolski M, Esler R, Kujawa ML, Bromage SJ, Oakley N, Adeyoju A, Brown SC, Brough R, Sinclair A, Collins GN (February 2014). \"Diethylstilboestrol for the treatment of prostate cancer: past, present and future\". Scand J Urol. 48 (1): 4–14. doi:10.3109/21681805.2013.861508. PMID 24256023.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":40,"type":"book","title":"Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CM (December 1988). \"The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma\". J. Urol. 140 (6): 1460–5. doi:10.1016/S0022-5347(17)42073-8. PMID 2973529.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":41,"type":"book","title":"Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD (June 1996). \"Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration\". Urology. 47 (6): 882–4. doi:10.1016/S0090-4295(96)00048-9. PMID 8677581.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":42,"type":"book","title":"Greschik H, Flaig R, Renaud JP, Moras D (August 2004). \"Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity\". The Journal of Biological Chemistry. 279 (32): 33639–46. doi:10.1074/jbc.M402195200. PMID 15161930.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":43,"type":"book","title":"Pugeat MM, Dunn JF, Nisula BC (July 1981). \"Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma\". J. Clin. Endocrinol. Metab. 53 (1): 69–75. doi:10.1210/jcem-53-1-69. PMID 7195405.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":44,"type":"book","title":"Oelschläger, Herbert; Rothley, Dietrich; Dunzendorfer, Udo (1988). \"New Results on the Pharmacokinetics of Fosfestrol\". Urologia Internationalis. 43 (1): 15–23. doi:10.1159/000281427. ISSN 1423-0399.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":45,"type":"book","title":"Droz JP, Kattan J, Bonnay M, Chraibi Y, Bekradda M, Culine S (February 1993). \"High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancer\". Cancer. 71 (3 Suppl): 1123–30. doi:10.1002/1097-0142(19930201)71:3+<1123::AID-CNCR2820711434>3.0.CO;2-T. PMID 8428334.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":46,"type":"book","title":"Chambers P, Günzel P (12 March 2013). Mechanism of Toxic Action on Some Target Organs: Drugs and Other Substances. Springer Science & Business Media. pp. 276–. ISBN 978-3-642-67265-1.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":47,"type":"book","title":"Couse JF, Korach KS (December 2004). \"Estrogen receptor-alpha mediates the detrimental effects of neonatal diethylstilbestrol (DES) exposure in the murine reproductive tract\". Toxicology. 205 (1–2): 55–63. doi:10.1016/j.tox.2004.06.046. PMID 15458790.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":48,"type":"book","title":"Vitamins and Hormones. Academic Press. 1945. pp. 233–. ISBN 978-0-08-086600-0.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":49,"type":"book","title":"Camille Georges Wermuth; David Aldous; Pierre Raboisson; Didier Rognan (1 July 2015). The Practice of Medicinal Chemistry. Elsevier Science. pp. 244–245. ISBN 978-0-12-417213-5.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":50,"type":"book","title":"Maximov PY, McDaniel RE, Jordan VC (23 July 2013). Tamoxifen: Pioneering Medicine in Breast Cancer. Springer Science & Business Media. pp. 3–. ISBN 978-3-0348-0664-0.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":51,"type":"book","title":"Ravina E (11 January 2011). T he Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons. pp. 177–. ISBN 978-3-527-32669-3.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":52,"type":"book","title":"Sneader W (31 October 2005). Drug Discovery: A History. John Wiley & Sons. pp. 196–197. ISBN 978-0-470-01552-0.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":53,"type":"book","title":"Dodds EC, Goldberg L, Lawson W, Robinson R (1938). \"Estrogenic activity of certain synthetic compounds\". Nature. 141 (3562): 247–8. doi:10.1038/141247b0.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":54,"type":"book","title":"Dodds EC (1957). Biochemical contributions to endocrinology; experiments in hormonal research. Stanford: Stanford University Press. OCLC 1483899.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":55,"type":"book","title":"Meyers R (1983). D.E.S., the bitter pill. New York: Seaview/Putnam. ISBN 0-399-31008-8.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":56,"type":"book","title":"Langston N (2010). Toxic bodies: Hormone disruptors and the legacy of DES. New Haven, CT: Yale University Press. ISBN 978-0-300-13607-4.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":57,"type":"book","title":"Seaman B (2003). The greatest experiment ever performed on women: Exploding the estrogen myth. New York: Hyperion. ISBN 978-0-7868-6853-7.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":58,"type":"book","title":"Huggins C, Hodges CV (1972). \"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate\". CA. 22 (4): 232–40. doi:10.3322/canjclin.22.4.232. PMID 4625049.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":59,"type":"book","title":"\"Prostate cancer yields to a drug\". The New York Times. 15 December 1943. p. 29.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":60,"type":"book","title":"The Leuprolide Study Group (November 1984). \"Leuprolide versus diethylstilbestrol for metastatic prostate cancer\". The New England Journal of Medicine. 311 (20): 1281–6. doi:10.1056/NEJM198411153112004. PMID 6436700.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":61,"type":"book","title":"Dutton DB (1988). Worse than the disease: pitfalls of medical progress. Cambridge: Cambridge University Press. ISBN 0-521-34023-3.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":62,"type":"book","title":"Physicians' desk reference to pharmaceutical specialties and biologicals (15th ed.). Oradell NJ: Medical Economics. 1961. p. 625. ISBN 0-00-093447-X.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":63,"type":"book","title":"Dieckmann WJ, Davis ME, Rynkiewicz LM, Pottinger RE (November 1953). \"Does the administration of diethylstilbestrol during pregnancy have therapeutic value?\". American Journal of Obstetrics and Gynecology. 66 (5): 1062–81. doi:10.1016/S0002-9378(16)38617-3. PMID 13104505.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":64,"type":"book","title":"Apfel RJ, Fisher SM (1984). To do no harm: DES and the dilemmas of modern medicine. New Haven: Yale University Press. ISBN 0-300-03192-0.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":65,"type":"book","title":"United States Food and Drug Administration (1971). \"Certain estrogens for oral or parenteral use. Drugs for human use; drug efficacy study implementation\". Fed Regist. 36 (217): 21537–8.; 36 FR 21537","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":66,"type":"book","title":"FDA (1975). \"Certain estrogens for oral use. Notice of withdrawal of approval of new drug applications\". Fed Regist. 40 (25): 5384.; 25 FR 5384","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":67,"type":"book","title":"Zuger A (2009-07-27). \"At What Height, Happiness? A Medical Tale\". The New York Times. NY Times.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":68,"type":"book","title":"Council on Drugs (1960). \"Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients\". JAMA. 172 (12): 1271–83. doi:10.1001/jama.1960.03020120049010.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":69,"type":"book","title":"Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S (January 1981). \"Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer\". The New England Journal of Medicine. 304 (1): 16–21. doi:10.1056/NEJM198101013040104. PMID 7001242.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":70,"type":"book","title":"Goodwin WE, Cummings RH (March 1984). \"Squamous metaplasia of the verumontanum with obstruction due to hypertrophy: long-term effects of estrogen on the prostate in an aging male-to-female transsexual\". The Journal of Urology. 131 (3): 553–4. doi:10.1016/s0022-5347(17)50493-0. PMID 6199525.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":71,"type":"book","title":"Lehrman KL (February 1976). \"Pulmonary embolism in a transsexual man taking diethylstilbestrol\". JAMA. 235 (5): 532–3. doi:10.1001/jama.1976.03260310046024. PMID 946104.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":72,"type":"book","title":"Seyler LE, Canalis E, Spare S, Reichlin S (July 1978). \"Abnormal gonadotropin secretory responses to LRH in transsexual women after diethylstilbestrol priming\". The Journal of Clinical Endocrinology and Metabolism. 47 (1): 176–83. doi:10.1210/jcem-47-1-176. PMID 122396.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":73,"type":"book","title":"Kuchera LK (October 1971). \"Postcoital contraception with diethylstilbestrol\". JAMA. 218 (4): 562–3. doi:10.1001/jama.218.4.562. PMID 5171004.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":74,"type":"book","title":"FDA (1975). \"Diethylstilbestrol as posticoital oral contraceptive; patient labeling\". Fed Regist. 40 (25): 5451–5.; 40 FR 5451","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":75,"type":"book","title":"FDA (1975). \"Estrogens for oral or parenteral use. Drugs for human use; drug efficacy study; amended notice\". Fed Regist. 40 (39): 8242.; 39 FR 8242","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":76,"type":"book","title":"Hatcher RA, Stewart GK, Stewart F, Guest F, Josephs N, Dale J (1982). Contraceptive Technology 1982–1983. New York: Irvington Publishers. pp. 152–7. ISBN 0-8290-0705-9.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":77,"type":"book","title":"FDA (1978). \"Estrogens for postpartum breast engorgement\". Fed Regist. 43 (206): 49564–7.; 43 FR 49564","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":78,"type":"book","title":"Lavoie D (9 January 2013). \"DES Pregnancy Drug Lawsuit: Settlement Reached Between Melnick Sisters And Eli Lilly And Co\". Huffington Post. Archived from the original on 10 January 2013. Retrieved 19 March 2014.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":79,"type":"book","title":"West-Taylor Z. \"The Alan Turing Law – a Formal Pardon for Unpardonable Homophobia\". Affinity magazine. Retrieved 3 December 2016.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":80,"type":"book","title":"\"Urinary Incontinence\". Merck Veterinary Manual. Merck Veterinary Manual. Retrieved 30 November 2012.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":81,"type":"book","title":"Harris RM, Waring RH (June 2012). \"Diethylstilboestrol--a long-term legacy\". Maturitas. 72 (2): 108–12. doi:10.1016/j.maturitas.2012.03.002. PMID 22464649.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":82,"type":"book","title":"Gandhi R, Snedeker S (2000-06-01). \"Consumer Concerns About Hormones in Food\". Fact Sheet #37, June 2000. Program on Breast Cancer and Environmental Risk Factors, Cornell University. Archived from the original on 2011-07-19. Retrieved 2011-07-20.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false}],"recommendReferences":null,"auditState":2,"lemmaLevel":1,"origin":0,"originEnTitle":null,"originZhTitle":null,"pv":2575,"auditType":2,"synonyms":["丙酸己烯雌酚","乙烯雌酚"],"showEditTime":"2020.08.25 12:57","auditors":[{"uid":5567290,"name":"人间小太阳","pic":"https://web.archive.org/web/20221029032313/https://cache.soso.com/qlogo/g?b=oidb&k=4xjGfuUZbbjZEI7OAVIVEg&s=100&t=1609215301","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":250,"partnerIdCreateTime":1598322359,"partnerIdPoped":true}],"hasZhishiNav":true,"auditInfos":{"0":[{"versionId":"0","auditTime":1598337350,"auditorId":5567290,"auditUser":{"uid":5567290,"name":"人间小太阳","pic":"https://web.archive.org/web/20221029032313/https://cache.soso.com/qlogo/g?b=oidb&k=4xjGfuUZbbjZEI7OAVIVEg&s=100&t=1609215301","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":250,"partnerIdCreateTime":1598322359,"partnerIdPoped":true},"auditReason":"","auditSuggest":"简单修改","auditResult":2,"auditAnnotations":null}]},"isHistory":false};</script><script crossorigin="anonymous" src="./120.己烯雌酚 - 搜狗科学百科_files/aegis.min.js.download"></script><script crossorigin="anonymous" src="./120.己烯雌酚 - 搜狗科学百科_files/main_2020092401.js.download"></script><script crossorigin="anonymous" src="./120.己烯雌酚 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./120.己烯雌酚 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./120.己烯雌酚 - 搜狗科学百科_files/jquery-1.11.1.min.js.download"></script><script crossorigin="anonymous" src="./120.己烯雌酚 - 搜狗科学百科_files/main_2022062701.js.download"></script><script crossorigin="anonymous" src="./120.己烯雌酚 - 搜狗科学百科_files/main_66bbe21.js.download"></script><script crossorigin="anonymous" src="./120.己烯雌酚 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./120.己烯雌酚 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./120.己烯雌酚 - 搜狗科学百科_files/main_edf0f08.js.download"></script>
</body></html>